<?xml version="1.0" encoding="iso-8859-1"?>
<!-- generator="FeedCreator 1.7.2" -->
<rss version="2.0">
    <channel>
        <title>Dermatologic Therapy via MedWorm.com</title>
        <description>MedWorm.com provides a medical RSS filtering service. Over 6000 RSS medical sources are combined and output via different filters. This feed contains the latest items from the 'Dermatologic Therapy' source.</description>
        <link><![CDATA[http://www.medworm.com/rss/search.php?qu=Dermatologic+Therapy&t=Dermatologic+Therapy&s=Search&f=source]]></link>
        <lastBuildDate>Sat, 20 Mar 2010 14:05:28 +0100</lastBuildDate>
        <item>
            <title>Topical Boswellic acids for treatment of photoaged skin</title>
            <link>http://www.medworm.com/index.php?rid=3186851&amp;cid=s_31737_12_f&amp;fid=31737&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1529-8019.2009.01284.x</link>
            <description>Boswellic acids (BAs) are pentacyclic triterpenes extracted from the gum resins of the tropical tree Boswellia serrata. They are orally administered in traditional Indian medicine for the treatment of several inflammatory disease and cancer because of their anti-inflammatory and immunomodulatory activities as well as stimulatory effects on fibroblasts. The present authors have investigated efficacy, tolerability, and safety of a base cream containing 0.5% BAs in the treatment of clinical manifestations of photoaging of facial skin with a randomized, double-blind, placebo-controlled, split-face study. Fifteen female volunteers applied the creams with or without BAs on the half sides of the face once daily for 30 days. Significant improvements of the Dover's global score for photoaging, tact...</description>
            <author>Dermatologic Therapy</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3186851</comments>
            <pubDate>Tue, 19 Jan 2010 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">3186851</guid>        </item>
        <item>
            <title>Treatment of disseminated granuloma annulare with allopurinol: case report</title>
            <link>http://www.medworm.com/index.php?rid=3186850&amp;cid=s_31737_12_f&amp;fid=31737&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1529-8019.2009.01283.x</link>
            <description>Granuloma annulare (GA) is a rare disease characterized by granulomatous inflammation of the dermis. A variant form of the disease, disseminated granuloma annulare (DGA), can be observed in about 15% of affected patients. Localized GA is likely to resolve spontaneously within months or a few years, whereas DGA can persist for decades. Various therapies have been suggested in these cases, but none of them has been demonstrated to be consistently efficacious. Allopurinol has been successfully used in granulomatous diseases such as sarcoidosis or reactions to polymethylmethacrylate spheres; therefore, we decided to evaluate the possible efficacy of this drug in three patients with long-lasting, therapy-resistant DGA. (Source: Dermatologic Therapy)</description>
            <author>Dermatologic Therapy</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3186850</comments>
            <pubDate>Tue, 19 Jan 2010 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">3186850</guid>        </item>
        <item>
            <title>Eccrine syringofibroadenoma radiation treatment of an unusual presentation</title>
            <link>http://www.medworm.com/index.php?rid=3186849&amp;cid=s_31737_12_f&amp;fid=31737&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1529-8019.2009.01282.x</link>
            <description>Benign skin diseases have seldom been treated with radiotherapy, unless resistant to other treatments. Eccrine syringofibroadenoma (ESFA) is a rare benign eccrine tumor. ESFA very rarely presents bilateral lesions, and seldom a nonsurgical treatment has been proposed. An exceptional case of bilateral ESFA of the foot is presented; radiotherapy was effective in treating both lesions with good cosmetic results. (Source: Dermatologic Therapy)</description>
            <author>Dermatologic Therapy</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3186849</comments>
            <pubDate>Tue, 19 Jan 2010 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">3186849</guid>        </item>
        <item>
            <title>Correlation between BMI and PASI in patients affected by moderate to severe psoriasis undergoing biological therapy</title>
            <link>http://www.medworm.com/index.php?rid=3186848&amp;cid=s_31737_12_f&amp;fid=31737&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1529-8019.2009.01281.x</link>
            <description>Obesity is common in psoriatic patients, and it has been shown to be important for many aspects of the condition. In particular, low-calorie diets can improve the symptoms and response to treatment in pustular psoriasis. The present study investigates the influence of body-weight alteration on the disease's clinical manifestations in moderate to severe psoriasis patients treated with biological drugs. Finally, the influence of a caloric restriction was assessed. This observational transversal study enrolled 33 patients attending our Severe Psoriasis Outpatient Clinic, who were treated with biological drugs. Body Mass Index (BMI) was used as a diagnostic indicator of being overweight and of obesity. Waist circumference was also measured. Body weight and Psoriasis Area Severity Index (PASI) ...</description>
            <author>Dermatologic Therapy</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3186848</comments>
            <pubDate>Tue, 19 Jan 2010 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">3186848</guid>        </item>
        <item>
            <title>Cost-effectiveness analysis of TNF-&amp;#x03B1; blockers for the treatment of chronic plaque psoriasis in the perspective of the Italian health-care system</title>
            <link>http://www.medworm.com/index.php?rid=3186847&amp;cid=s_31737_12_f&amp;fid=31737&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1529-8019.2009.01280.x</link>
            <description>The objectives of this study was to perform a cost-effectiveness analysis of infliximab compared with other anti-tumor necrosis factor-[alpha] agents for the treatment of psoriasis in Italy. The incremental cost-effectiveness ratio per patients achieving at least 75% improvement in the psoriasis area and severity index assessed over 24- and 48[ndash]50-week periods was calculated. Efficacy data were drawn from randomized controlled trials when available or from open label studies. Considering patients achieving psoriasis area and severity index at week 24 and 48[ndash]50, infliximab was dominant (more effective and less costly) over etanercept given at 50 mg twice weekly. In contrast, infliximab was not dominant over etanercept at other dosages or over adalimumab. When considering the impa...</description>
            <author>Dermatologic Therapy</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3186847</comments>
            <pubDate>Tue, 19 Jan 2010 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">3186847</guid>        </item>
        <item>
            <title>Combined treatment of Favre-Racouchot syndrome with a superpulsed carbon dioxide laser: report of 50 cases</title>
            <link>http://www.medworm.com/index.php?rid=3186846&amp;cid=s_31737_12_f&amp;fid=31737&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1529-8019.2009.01279.x</link>
            <description>Nodular elastosis with cysts and comedones also known as Favre-Racouchot syndrome frequently occurs on actinically damaged skin of middle-aged or elderly Caucasian subjects. The disease usually affects simmetrically the skin mainly around the orbits. Treatment in the past has not been entirely satisfactory. Treatment of 50 patients with a superpulsed carbon dioxide laser in order to vaporize epidermis followed by extraction of cystic and comedonic material using soft pressure with a pair of forceps. Laser treatment was performed without previous topical or intralesional anesthetics because no pain was reported using the described laser parameters. Our combined therapeutic approach was safe and effective in all the patients, guaranteeing an excellent cosmetic result. The combined technique ...</description>
            <author>Dermatologic Therapy</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3186846</comments>
            <pubDate>Tue, 19 Jan 2010 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">3186846</guid>        </item>
        <item>
            <title>Unusual presentation of tuberculosis in an infliximab-treated patient &amp;#x2013; which is the correct TB screening before starting a biologic?</title>
            <link>http://www.medworm.com/index.php?rid=3186845&amp;cid=s_31737_12_f&amp;fid=31737&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1529-8019.2009.01278.x</link>
            <description>We report the case of a psoriatic patient, who, despite a negative screening for infection by M. tuberculosis including both tuberculin skin test (TST) and chest X-ray, developed after 4 months of infliximab treatment, a severe pulmonary, lymphnodal and intestinal tuberculosis during infliximab treatment. (Source: Dermatologic Therapy)</description>
            <author>Dermatologic Therapy</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3186845</comments>
            <pubDate>Fri, 01 Jan 2010 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">3186845</guid>        </item>
        <item>
            <title>Original Article: Compounding dermatologic preparations in developing countries</title>
            <link>http://www.medworm.com/index.php?rid=2960648&amp;cid=s_31737_12_f&amp;fid=31737&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1529-8019.2009.01277.x</link>
            <description>Access to medications and their proper use are essential in developing countries. An interdisciplinary team of dermatologists and pharmacists created a master list of preparations useful for treating the most common dermatologic disorders in tropical and equatorial areas. The first pilot project was done at Cardinal Leger Hospital in Leogane, Haiti. Training was given to local staff at that hospital in 2005. Four years later, the clinic continues to prepare and offer, at a reasonable price, drugs that the population needs. (Source: Dermatologic Therapy)</description>
            <author>Dermatologic Therapy</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2960648</comments>
            <pubDate>Wed, 04 Nov 2009 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">2960648</guid>        </item>
        <item>
            <title>Original Article: Superficial cutaneous fungal infections in tropical countries</title>
            <link>http://www.medworm.com/index.php?rid=2960647&amp;cid=s_31737_12_f&amp;fid=31737&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1529-8019.2009.01276.x</link>
            <description>Superficial fungal infections represent an important cause of morbidity for people worldwide, particularly in the tropics. Fungal infections affect the skin, hair, or the nails, and tend to thrive in the heat and humidity of tropical countries. Because of environmental and cultural factors unique to the tropics, the causative organisms and presentation of these infections may differ from those in industrialized countries. Treatment options include topical and systemic therapy. However, social and socioeconomic factors in developing tropical countries may necessitate different treatment approaches to achieve success. (Source: Dermatologic Therapy)</description>
            <author>Dermatologic Therapy</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2960647</comments>
            <pubDate>Wed, 04 Nov 2009 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">2960647</guid>        </item>
        <item>
            <title>Imported tropical diseases</title>
            <link>http://www.medworm.com/index.php?rid=2960646&amp;cid=s_31737_12_f&amp;fid=31737&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1529-8019.2009.01275.x</link>
            <description>are among the top three leading causes for morbidity and may affect up to 8% of returning travelers. Because the spectrum of dermatological manifestations seen in travelers is broad, it can be challenging for physicians to recognize and treat such conditions in a timely and efficient manner. Therefore, the present review highlights common imported tropical diseases with a focus on treatment regimens. Specifically, cutaneous larva migrans, myiasis, swimmer's itch, mycetoma, Chagas disease, and leishmaniasis are discussed. As awareness increases among travelers, immigrants, and health care providers regarding imported tropical diseases, early intervention and proper diagnosis can ensue, thus reducing morbidity and mortality in affected individuals. (Source: Dermatologic Therapy)</description>
            <author>Dermatologic Therapy</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2960646</comments>
            <pubDate>Wed, 04 Nov 2009 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">2960646</guid>        </item>
        <item>
            <title>Treatment of leprosy/Hansen's disease in the early 21st century</title>
            <link>http://www.medworm.com/index.php?rid=2960645&amp;cid=s_31737_12_f&amp;fid=31737&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1529-8019.2009.01274.x</link>
            <description>Leprosy, or Hansen's disease (HD), is caused by Mycobacterium leprae, a slowly dividing mycobacterium that has evolved to be an intracellular parasite, causing skin lesions and nerve damage. Less than 5% of people exposed to M. leprae develop clinical disease. Host cell-mediated resistance determines whether an individual will develop paucibacillary or multibacillary disease. Hansen's disease is a worldwide disease with about 150 new cases reported annually in the United States. Effective anti-mycobacterial treatments are available, and many patients experience severe reversal and erythema nodosum leprosum reactions that also require treatment. Leprosy has been the target of a World Health Organization multiple drug therapy campaign to eliminate it as a national public health problem in me...</description>
            <author>Dermatologic Therapy</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2960645</comments>
            <pubDate>Wed, 04 Nov 2009 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">2960645</guid>        </item>
        <item>
            <title>Cutaneous ectoparasites</title>
            <link>http://www.medworm.com/index.php?rid=2960644&amp;cid=s_31737_12_f&amp;fid=31737&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1529-8019.2009.01273.x</link>
            <description>Parasites inhabit many places in the world. Some of these can inhabit the human skin or body. Many of these have been eradicated in the developed countries but persist in some tropical environments that are fun places to visit. Visitors can bring such parasites home with them such as scabies, cutaneous larva migrans, tungiasis and myiasis. Their clinical manifestations and treatment are presented for physicians evaluating and treating travelers from exotic places. (Source: Dermatologic Therapy)</description>
            <author>Dermatologic Therapy</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2960644</comments>
            <pubDate>Wed, 04 Nov 2009 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">2960644</guid>        </item>
        <item>
            <title>Cutaneous and mucocutaneous leishmaniasis</title>
            <link>http://www.medworm.com/index.php?rid=2960643&amp;cid=s_31737_12_f&amp;fid=31737&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1529-8019.2009.01272.x</link>
            <description>Leishmaniasis is a cluster of diseases caused by protozoa in the genus Leishmania. There are three basic clinical forms: cutaneous, mucocutaneous, and visceral leishmaniasis. The present review focuses on the diagnosis and treatment of cutaneous and mucocutaneous leishmaniasis. Characteristics of both the human host and the parasite species influence the clinical disease manifestations that range from asymptomatic exposure, to self-healing skin ulcers, to life-threatening widespread destructive ulcerations. Whether through medical treatment or through spontaneous resolution, skin ulcerations generally result in disfiguring scars with significant social and economic impact. Tests to confirm the diagnosis should be performed on patients who have recently visited endemic areas and have skin o...</description>
            <author>Dermatologic Therapy</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2960643</comments>
            <pubDate>Wed, 04 Nov 2009 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">2960643</guid>        </item>
        <item>
            <title>Filariasis: diagnosis and treatment</title>
            <link>http://www.medworm.com/index.php?rid=2960642&amp;cid=s_31737_12_f&amp;fid=31737&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1529-8019.2009.01271.x</link>
            <description>Filariasis is an infectious disease of the lymphatics and subcutaneous tissues caused by nematodes or filariae. Carried by mosquito vectors, this disease causes millions of people to suffer from lymphedema and elephantiasis, characteristics of filariasis infection. This disease can be diagnosed through the identification of microfilariae in blood or skin samples, antigen detection, radiographic imaging, or polymerase chain reaction. Mass drug administration by the World Health Organization has helped to diminish the incidence of filariasis. However, continued research on new drugs and vaccinations will be needed to control and reduce the microfilarial levels in the human population. (Source: Dermatologic Therapy)</description>
            <author>Dermatologic Therapy</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2960642</comments>
            <pubDate>Wed, 04 Nov 2009 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">2960642</guid>        </item>
        <item>
            <title>Scabies and pyodermas &amp;#x2013; diagnosis and treatment</title>
            <link>http://www.medworm.com/index.php?rid=2960641&amp;cid=s_31737_12_f&amp;fid=31737&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1529-8019.2009.01270.x</link>
            <description>Scabies and pyodermas are two of the commonest skin infections in tropical settings. They affect large numbers of people, particularly children, and account for a large burden of disease for peripheral health care teams. Despite this there have been significant advances in our knowledge of these diseases, their impact and their management. However there is a need to evaluate these developments in this specific setting, tropical health and in the context of communities with limited resources. This section will describe these advances and the challenges that remain. (Source: Dermatologic Therapy)</description>
            <author>Dermatologic Therapy</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2960641</comments>
            <pubDate>Wed, 04 Nov 2009 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">2960641</guid>        </item>
        <item>
            <title>Cutaneous leishmaniasis treated with itraconazole</title>
            <link>http://www.medworm.com/index.php?rid=2956196&amp;cid=s_31737_12_f&amp;fid=31737&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1529-8019.2009.01264.x</link>
            <description>We report a case of cutaneous Leishmaniasis in a young girl successfully treated with itraconazole. (Source: Dermatologic Therapy)</description>
            <author>Dermatologic Therapy</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2956196</comments>
            <pubDate>Tue, 03 Nov 2009 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">2956196</guid>        </item>
        <item>
            <title>An overview of delayed pressure urticaria with special emphasis on pathogenesis and treatment</title>
            <link>http://www.medworm.com/index.php?rid=2956195&amp;cid=s_31737_12_f&amp;fid=31737&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1529-8019.2009.01268.x</link>
            <description>Delayed pressure urticaria (DPU) is a physical urticaria characterized by the development of deep swellings at sites of pressure application on the skin. Etiopathogenesis of DPU is still unknown, although the available evidence suggests the involvement of mast cells through non-immunologic mechanisms and the role of several mediators beyond histamine, such as proinflammatory cytokines. The management of DPU is complex, also considering that prevention is very difficult and DPU frequently coexists with chronic &quot;idiopathic&quot; urticaria. Moreover, H1-antihistamines, which are the mainstay of treatment for common urticaria, usually provide less satisfactory results as compared with other urticarias. Therefore, numerous treatment alternatives have been proposed for severe refractory cases, such a...</description>
            <author>Dermatologic Therapy</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2956195</comments>
            <pubDate>Tue, 03 Nov 2009 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">2956195</guid>        </item>
        <item>
            <title>Ultrasound evaluation of clobetasol propionate 0.05% foam application in psoriatic and healthy skin: a pilot study</title>
            <link>http://www.medworm.com/index.php?rid=2956194&amp;cid=s_31737_12_f&amp;fid=31737&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1529-8019.2009.01267.x</link>
            <description>The aim of the present study was to evaluate through ultrasound imaging the response to treatment of twice and once daily application of clobetasol propionate 0.05% foam on psoriatic skin as well as the atrophogenic potential of once daily application of the foam on healthy skin. The study included a total of 40 participants, 30 affected by Psoriasis vulgaris and 10 healthy volunteers. Patients with psoriasis were branched in two groups of 15 subjects: in the first group, clobetasol propionate 0.05% foam was applied twice daily for up to 2 weeks on targeted plaques, in the second group, it was applied once daily for up to 4 weeks. Ten healthy adult volunteers were instructed to apply the foam to a 4 × 4 cm area on the volar aspect of the forearm once daily for 4 weeks. Ultrasound evaluati...</description>
            <author>Dermatologic Therapy</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2956194</comments>
            <pubDate>Tue, 03 Nov 2009 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">2956194</guid>        </item>
        <item>
            <title>Treatment of erythrodermic psoriasis in HCV+ patient with adalimumab</title>
            <link>http://www.medworm.com/index.php?rid=2956193&amp;cid=s_31737_12_f&amp;fid=31737&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1529-8019.2009.01266.x</link>
            <description>Erythrodermic psoriasis is a severe and disabling variant of psoriasis. The authors present the case of a 48-year-old man with psoriasis and hemophilia presented with a history of hepatitis C virus (HCV) infection treated with pegylated interferon alpha-2a and ribavirin therapy. At the end of antiviral therapy, skin manifestation progressively worsened, becoming erythrodermic, with lack of efficacy of steroid therapy. The authors decided to start biological therapy with induction dose of adalimumab (Humira, Abbott Laboratories, Abbott Park, Chicago, IL) 80 mg at Week 0 and 40 mg weekly. In our case, this resulted in a highly effective and safe treatment. (Source: Dermatologic Therapy)</description>
            <author>Dermatologic Therapy</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2956193</comments>
            <pubDate>Tue, 03 Nov 2009 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">2956193</guid>        </item>
        <item>
            <title>Fractional CO2 laser: a novel therapeutic device upon photobiomodulation of tissue remodeling and cytokine pathway of tissue repair</title>
            <link>http://www.medworm.com/index.php?rid=2956192&amp;cid=s_31737_12_f&amp;fid=31737&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1529-8019.2009.01265.x</link>
            <description>Minimally ablative fractional laser devices have gained acceptance as a preferred method for skin resurfacing. Notable improvements in facial rhytides, photodamage, acne scarring, and skin laxity have been reported. The aim of the present work was to compare how different CO2 laser fluences, by modulating the secretory pathway of cytokines, are able to influence the wound-healing process, and how these fluences are associated with different clinical results. Eighteen patients, all with photodamaged skin, were treated using a fractional CO2 laser (SmartXide DOT, Deka M.E.L.A., Florence, Italy) with varying laser fluences (2.07, 2.77, and 4.15 J/cm2). An immunocytochemical study was performed at defined end points in order to obtain information about specific cytokines of the microenvironmen...</description>
            <author>Dermatologic Therapy</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2956192</comments>
            <pubDate>Tue, 03 Nov 2009 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">2956192</guid>        </item>
        <item>
            <title>Tropical dermatology and medicine</title>
            <link>http://www.medworm.com/index.php?rid=2960640&amp;cid=s_31737_12_f&amp;fid=31737&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1529-8019.2009.01269.x</link>
            <description>(Source: Dermatologic Therapy)</description>
            <author>Dermatologic Therapy</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2960640</comments>
            <pubDate>Sun, 01 Nov 2009 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">2960640</guid>        </item>
        <item>
            <title>Cutaneous lesions as initial signs of interferon &amp;#x03B1;-induced sarcoidosis: report of three new cases and review of the literature</title>
            <link>http://www.medworm.com/index.php?rid=2956191&amp;cid=s_31737_12_f&amp;fid=31737&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1529-8019.2009.01263.x</link>
            <description>We report three new cases of mono-localized, purely cutaneous IFN[alpha]-induced sarcoidosis. In addition, an extensive review of the literature, with special attention to skin involvement, was performed through a PubMed search. The analysis of the retrieved articles showed that cutaneous lesions are frequent signs of IFN-induced sarcoidosis. Skin involvement is documented in 56% of the reports and it appears among the presenting and diagnostic signs of a sarcoid reaction in 51%. Special attention to dermatologic signs is imperative in the course of IFN therapy because even minimal skin involvement may offer a clue to an early diagnosis of IFN-induced sarcoidosis. (Source: Dermatologic Therapy)</description>
            <author>Dermatologic Therapy</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2956191</comments>
            <pubDate>Sun, 01 Nov 2009 00:00:00 +0100</pubDate>
            <guid isPermaLink="false">2956191</guid>        </item>
        <item>
            <title>Can short courses of systemic corticosteroids truly cause osteonecrosis?</title>
            <link>http://www.medworm.com/index.php?rid=2753982&amp;cid=s_31737_12_f&amp;fid=31737&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1529-8019.2009.01262.x</link>
            <description>One of the most feared complications of long-term corticosteroid therapy is osteonecrosis (avascular necrosis, aseptic necrosis). There is, no doubt, a causal role for systemic corticosteroids inducing osteonecrosis with such chronic therapy. The controversy involves whether short-term ( (Source: Dermatologic Therapy)</description>
            <author>Dermatologic Therapy</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2753982</comments>
            <pubDate>Mon, 31 Aug 2009 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">2753982</guid>        </item>
        <item>
            <title>Should dermatologists prescribe hormonal contraceptives for acne?</title>
            <link>http://www.medworm.com/index.php?rid=2753981&amp;cid=s_31737_12_f&amp;fid=31737&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1529-8019.2009.01261.x</link>
            <description>One of the primary factors contributing to the development of acne vulgaris is excess sebum. Sebaceous glands and sebum excretion are regulated, at least in part, by androgen hormones. Acne treatments that block this androgen effect include spironolactone and combination oral contraceptives (COC). Three COC are now FDA approved to treat moderate acne. Dermatologists must become experts at prescribing these hormonal contraceptives. Likewise, it is vital to be aware of contraindications to hormonal contraceptive therapy. Proper patient selection relies on an appropriate medical history and an assessment of blood pressure. A pelvic exam and/or Papanicolaou smear are not required prior to initiating therapy with a COC. It is important to counsel patients about potential adverse effects of COC ...</description>
            <author>Dermatologic Therapy</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2753981</comments>
            <pubDate>Mon, 31 Aug 2009 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">2753981</guid>        </item>
        <item>
            <title>Clinical risk management of Stevens&amp;#x2013;Johnson syndrome/toxic epidermal necrolysis spectrum</title>
            <link>http://www.medworm.com/index.php?rid=2753980&amp;cid=s_31737_12_f&amp;fid=31737&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1529-8019.2009.01260.x</link>
            <description>Clinical risk management concedes that risk is inherent to all health-care processes. Stevens[ndash]Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are rare but potentially life-threatening reactions to medications. Risk management should be considered prior to starting, during, and after therapy. Prior to starting therapy, risks that need to be assessed include any specific patient groups that may be at greater risk for the development of SJS/TEN. Gene testing is in place for Chinese and Thai patients who are going to be exposed to carbamazepine. During therapy, it is important to recognize SJS/TEN as a possible adverse drug reaction. Diagnostic criteria have changed, and more data exist on drugs with an increased risk. Although there is no standardized treatment for all patie...</description>
            <author>Dermatologic Therapy</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2753980</comments>
            <pubDate>Mon, 31 Aug 2009 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">2753980</guid>        </item>
        <item>
            <title>Long-term efficacy of biologics in the treatment of psoriasis: what do we really know?</title>
            <link>http://www.medworm.com/index.php?rid=2753979&amp;cid=s_31737_12_f&amp;fid=31737&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1529-8019.2009.01259.x</link>
            <description>Psoriasis is a chronic inflammatory condition that often requires life-long treatment. Conventional therapies have not fully met the needs of psoriatic patients, because of limited efficacy, adverse effects with cumulative use, and patient inconvenience. In the past decade, biologic immunotherapies have become accepted treatments for psoriasis as a result of perceived efficacy and safety on the part of patients and practitioners. However, most data on these medications come from relatively limited short-term trials. In this review, we will focus on the available long-term data on the efficacy of the biologic agents. We will emphasize the strengths and weakness of the available data of the biologic agents that are Food and Drug Administration (FDA)-approved for the treatment of moderate to ...</description>
            <author>Dermatologic Therapy</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2753979</comments>
            <pubDate>Mon, 31 Aug 2009 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">2753979</guid>        </item>
        <item>
            <title>Is there truly a risk of lymphoma from biologic therapies?</title>
            <link>http://www.medworm.com/index.php?rid=2753978&amp;cid=s_31737_12_f&amp;fid=31737&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1529-8019.2009.01258.x</link>
            <description>The treatment of psoriasis has undergone a revolution with the advent of biologic therapies, including infliximab, etanercept, adalimumab, efalizumab, and alefacept. Biologics are generally safe and well tolerated. However, there has been concern over the risk of lymphoma with use of these agents because of their immunosuppressive properties. This review summarizes the current evidence in regards to lymphoma risk with biologic therapy obtained from case reports and case series, observational studies, clinical trials, and meta-analyses. The majority of data for T-cell inhibitors comes from case reports and relatively small, short-term clinical trials. In addition to published case reports and case series, TNF-[alpha] inhibitors have also been studied extensively in large cohort studies and ...</description>
            <author>Dermatologic Therapy</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2753978</comments>
            <pubDate>Mon, 31 Aug 2009 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">2753978</guid>        </item>
        <item>
            <title>Controversies in the management of the cutaneous T cell lymphomas</title>
            <link>http://www.medworm.com/index.php?rid=2753977&amp;cid=s_31737_12_f&amp;fid=31737&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1529-8019.2009.01257.x</link>
            <description>The primary cutaneous T cell lymphomas (CTCL) encompass all malignancies of the T cell where the skin is the primary organ of involvement. The diagnosis of a CTCL variant can be detoured by a number of obstacles including the slow evolution of the disease into a classic clinical and pathologic pattern. A realistic goal of early stage treatment is to reduce the likelihood of progression to a more advanced stage, not to achieve a cure. No studies have adequately compared the different systemic agents in patients with advanced CTCL so the clinician is left to act in the best interest of the patient with what evidence is available. When using the systemic agents, a &quot;start low and go slow&quot; strategy may offer patients several advantages. Dermatologists are uniquely trained to diagnose and to man...</description>
            <author>Dermatologic Therapy</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2753977</comments>
            <pubDate>Mon, 31 Aug 2009 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">2753977</guid>        </item>
        <item>
            <title>Topical antibiotics: therapeutic value or ecologic mischief?</title>
            <link>http://www.medworm.com/index.php?rid=2753976&amp;cid=s_31737_12_f&amp;fid=31737&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1529-8019.2009.01256.x</link>
            <description>Based on antibiotic prescribing data from 2003, dermatologists account annually for 8[ndash]9 million prescriptions for oral antibiotics, and 3[ndash]4 million prescriptions for topical antibiotics. Overall, much of the emphasis on concerns related to emergence of clinically significant antibiotic-resistant bacterial strains focuses on use of systemic antibiotics, however, topical antibiotic use may also have potential implications. The following article discusses the perspectives of the authors related to the potential therapeutic benefits and ecologic implications (&quot;ecologic mischief&quot;) of topical antibiotic therapy for specific indications encountered in ambulatory dermatology practice. (Source: Dermatologic Therapy)</description>
            <author>Dermatologic Therapy</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2753976</comments>
            <pubDate>Mon, 31 Aug 2009 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">2753976</guid>        </item>
        <item>
            <title>Controversies in Dermatologic Drug Therapy</title>
            <link>http://www.medworm.com/index.php?rid=2753975&amp;cid=s_31737_12_f&amp;fid=31737&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1529-8019.2009.01255.x</link>
            <description>(Source: Dermatologic Therapy)</description>
            <author>Dermatologic Therapy</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2753975</comments>
            <pubDate>Mon, 31 Aug 2009 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">2753975</guid>        </item>
        <item>
            <title>Erratum</title>
            <link>http://www.medworm.com/index.php?rid=2564643&amp;cid=s_31737_12_f&amp;fid=31737&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1529-8019.2009.01254.x</link>
            <description>(Source: Dermatologic Therapy)</description>
            <author>Dermatologic Therapy</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2564643</comments>
            <pubDate>Wed, 01 Jul 2009 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">2564643</guid>        </item>
        <item>
            <title>Monochromatic excimer light 308&amp;nbsp;nm in monotherapy and combined with topical khellin 4% in the treatment of vitiligo: a controlled study</title>
            <link>http://www.medworm.com/index.php?rid=2564642&amp;cid=s_31737_12_f&amp;fid=31737&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1529-8019.2009.01252.x</link>
            <description>Vitiligo is an acquired depigmentation disorder affecting 1[ndash]4% of the world's population. Conventional therapies include steroids, photosensitive topical agents, surgical treatments, and phototherapy. The aim of the study was to evaluate the efficacy of monochromatic excimer light 308 nm (MEL), both as a monotherapy and in combination with khellin 4% ointment in vitiligo. Forty-height patients (36 male and 12 female) affected with vitiligo were enrolled in this open prospective study. Patients were selected and divided into three groups: group I included 16 patients treated with MEL 308 nm once-weekly and oral vitamin E; group II included 16 patients treated with MEL 308 nm once-weekly combined with khellin 4% ointment (MEL-K) and oral vitamin E; group III (control group) included 16...</description>
            <author>Dermatologic Therapy</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2564642</comments>
            <pubDate>Wed, 01 Jul 2009 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">2564642</guid>        </item>
        <item>
            <title>Switch from etanercept to efalizumab in a psoriatic patient with HCV infection: a case report</title>
            <link>http://www.medworm.com/index.php?rid=2564641&amp;cid=s_31737_12_f&amp;fid=31737&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1529-8019.2009.01251.x</link>
            <description>We report a case of a patient affected by severe psoriasis and HCV infection. He underwent a first treatment with etenarcept with good clinical results and no change of his viral load. When etenarcept became ineffective, he received efalizumab, with a good control of his dermatological condition and a reduction of the viral load. (Source: Dermatologic Therapy)</description>
            <author>Dermatologic Therapy</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2564641</comments>
            <pubDate>Wed, 01 Jul 2009 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">2564641</guid>        </item>
        <item>
            <title>Focused UV-B narrowband microphototherapy (Biopsorin&amp;reg;). A new treatment for plaque psoriasis</title>
            <link>http://www.medworm.com/index.php?rid=2564640&amp;cid=s_31737_12_f&amp;fid=31737&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1529-8019.2009.01250.x</link>
            <description>We report here on a new focused phototherapy method releasing UV-B with a peak at 311 nm, which consists in the selective irradiation of single psoriatic patches with a new device equipped with a special optic fiber. The treatment is effective, safe and well tolerated. Psoriasis Area and Severity Index 75 is achieved in 64% of patients after 12 sessions of treatment. The Physician Global Assessment evaluation significantly improves in all treated patients. (Source: Dermatologic Therapy)</description>
            <author>Dermatologic Therapy</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2564640</comments>
            <pubDate>Wed, 01 Jul 2009 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">2564640</guid>        </item>
        <item>
            <title>Angiomatous reaction Kaposi-sarcoma-like as a side effect of topical corticosteroid therapy in lichen sclerosus of the penis</title>
            <link>http://www.medworm.com/index.php?rid=2564639&amp;cid=s_31737_12_f&amp;fid=31737&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1529-8019.2009.01249.x</link>
            <description>We report the case of a 74-year-old man presented with a 6-month history of nodular lesions localized on penis. The man had a previous history of genital lesions that had been diagnosed as LS and treated with long-term topical corticosteroid therapy. After 3 months of corticosteroid therapy, the patient observed the appearance of several nodular erythematous lesions on the penis with progressive disappearance of the clinical symptoms of LS. These purple to red asymptomatic angiomatoid nodules resembled the clinical features of Kaposi sarcoma. (Source: Dermatologic Therapy)</description>
            <author>Dermatologic Therapy</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2564639</comments>
            <pubDate>Wed, 01 Jul 2009 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">2564639</guid>        </item>
        <item>
            <title>Zoonoses of dermatologic interest</title>
            <link>http://www.medworm.com/index.php?rid=2564638&amp;cid=s_31737_12_f&amp;fid=31737&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1529-8019.2009.01248.x</link>
            <description>Zoonoses are infectious diseases that can be transmitted from animals to humans. Transmission occurs directly or through vectors such as ticks, mosquitoes, or flies. The causative agents include bacteria, parasites, viruses, and fungi. Domestic pets and livestock, as well as wild animals, can be the source of disease. In this summary, we will focus on a number of dermatologically relevant examples. (Source: Dermatologic Therapy)</description>
            <author>Dermatologic Therapy</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2564638</comments>
            <pubDate>Wed, 01 Jul 2009 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">2564638</guid>        </item>
        <item>
            <title>Caterpillars and moths</title>
            <link>http://www.medworm.com/index.php?rid=2564637&amp;cid=s_31737_12_f&amp;fid=31737&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1529-8019.2009.01247.x</link>
            <description>Lepidoptera (moths, butterflies, and caterpillars) are an uncommon cause of adverse reactions in humans. Most reactions to Lepidoptera are mild and self-limited; however, reactions in sensitive individuals and reactions to particular species can be severe and life threatening. Specific syndromes caused by Lepidoptera include erucism (cutaneous reactions from contact with caterpillars, moths, or cocoons), lepidopterism (systemic involvement), ophthalmia nodosa (ocular involvement), dendrolimiasis and pararamose (each with joint symptoms relating to a specific species of caterpillar), lonomism (a severe hemorrhagic disease related to Lonomia species), and seasonal ataxia (related to ingestion of Anaphe venata). In most cases, reactions to Lepidoptera can be treated symptomatically with promp...</description>
            <author>Dermatologic Therapy</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2564637</comments>
            <pubDate>Wed, 01 Jul 2009 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">2564637</guid>        </item>
        <item>
            <title>Bedbugs</title>
            <link>http://www.medworm.com/index.php?rid=2564636&amp;cid=s_31737_12_f&amp;fid=31737&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1529-8019.2009.01246.x</link>
            <description>Cimex lectularius (the &quot;bedbug&quot;) is an insect that feeds nocturnally, taking a requisite blood meal from a sleeping human or other parasitized host. Immunological reactions to bedbug saliva vary, but typically, bites yield erythematous and pruritic papules. The face and distal extremities, areas uncovered by sleeping clothes or blankets, are preferentially involved. Until the late 1990s, bedbug infestations in the United States were declining. Resurgence is attributed to increased travel and resistance to insecticides. Although hepatitis or human immunodeficiency virus is not effectively transmitted by the bedbug, pruritus and the fear and perceived violation of an infestation can be debilitating. Bedbugs are small but robust, and their ability to remain ensconced in crevices within the be...</description>
            <author>Dermatologic Therapy</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2564636</comments>
            <pubDate>Wed, 01 Jul 2009 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">2564636</guid>        </item>
        <item>
            <title>Mite infestations</title>
            <link>http://www.medworm.com/index.php?rid=2564635&amp;cid=s_31737_12_f&amp;fid=31737&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1529-8019.2009.01245.x</link>
            <description>This article will review etiology, clinical manifestation, and treatment of mite infestations. (Source: Dermatologic Therapy)</description>
            <author>Dermatologic Therapy</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2564635</comments>
            <pubDate>Wed, 01 Jul 2009 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">2564635</guid>        </item>
        <item>
            <title>Diagnosis and treatment of tick infestation and tick-borne diseases with cutaneous manifestations</title>
            <link>http://www.medworm.com/index.php?rid=2564634&amp;cid=s_31737_12_f&amp;fid=31737&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1529-8019.2009.01244.x</link>
            <description>This article reviews the presentation of tick-borne illnesses and the medical management of these diseases. Among others, diseases such as ehrlichiosis, anaplasmosis, babesiosis, tularemia, borrelioses, tick-borne encephalitides, rickettsial spotted fevers, and tick typhus are discussed in this article. The recognition of skin manifestations associated with these diseases is paramount to early diagnosis and treatment initiation. (Source: Dermatologic Therapy)</description>
            <author>Dermatologic Therapy</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2564634</comments>
            <pubDate>Wed, 01 Jul 2009 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">2564634</guid>        </item>
        <item>
            <title>Scabies</title>
            <link>http://www.medworm.com/index.php?rid=2564633&amp;cid=s_31737_12_f&amp;fid=31737&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1529-8019.2009.01243.x</link>
            <description>is an ectoparasite caused by the mite Sarcoptes scabiei var hominis, an obligate human parasite. There are about 300 million cases of scabies in the world each year. Common predisposing factors are overcrowding, immigration, poor hygiene, poor nutritional status, homelessness, dementia, and sexual contact. Direct skin-to-skin contact between 15 and 20 minutes is needed to transfer the mites from one person to another. The diagnosis suspected with a clinical history of itch, worse at night, affecting other family members, clinical distribution, and appearance. Definite diagnosis relies on microscopic identification of the mites, eggs, or fecal pellets with 10% potassium hydroxide, ink enhancement, tetracycline fluorescence tests, or mineral oil; other methods include: epiluminescence light...</description>
            <author>Dermatologic Therapy</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2564633</comments>
            <pubDate>Wed, 01 Jul 2009 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">2564633</guid>        </item>
        <item>
            <title>Treatment of head lice</title>
            <link>http://www.medworm.com/index.php?rid=2564632&amp;cid=s_31737_12_f&amp;fid=31737&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1529-8019.2009.01242.x</link>
            <description>Pediculosis capitis, or head lice, is a common infestation among children worldwide. Multiple therapies exist for the treatment of this condition, including topical pediculicides and oral medications. When used in combination with environmental decontamination, these drugs can be very effective in eradicating head lice infestation without significant adverse events. The present study discusses the use of available over-the-counter and prescription treatments, including pyrethroids and permethrin, lindane, malathion, ivermectin, and trimethoprim-sulfamethoxazole, in the treatment of head lice. (Source: Dermatologic Therapy)</description>
            <author>Dermatologic Therapy</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2564632</comments>
            <pubDate>Wed, 01 Jul 2009 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">2564632</guid>        </item>
        <item>
            <title>Treatment of infestations, vector-borne, and zoonotic diseases</title>
            <link>http://www.medworm.com/index.php?rid=2564631&amp;cid=s_31737_12_f&amp;fid=31737&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1529-8019.2009.01241.x</link>
            <description>(Source: Dermatologic Therapy)</description>
            <author>Dermatologic Therapy</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2564631</comments>
            <pubDate>Tue, 30 Jun 2009 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">2564631</guid>        </item>
        <item>
            <title>Erratum</title>
            <link>http://www.medworm.com/index.php?rid=2391505&amp;cid=s_31737_12_f&amp;fid=31737&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1529-8019.2009.01253.x</link>
            <description>(Source: Dermatologic Therapy)</description>
            <author>Dermatologic Therapy</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2391505</comments>
            <pubDate>Wed, 06 May 2009 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">2391505</guid>        </item>
        <item>
            <title>Key opinion leaders: where they come from and how that affects the drugs you prescribe</title>
            <link>http://www.medworm.com/index.php?rid=2391504&amp;cid=s_31737_12_f&amp;fid=31737&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1529-8019.2009.01240.x</link>
            <description>Key opinion leaders (KOLs), also known as thought leaders, are the experts in their field upon whom we depend for original research leading to disease understanding and new therapies. We rely on them to write the articles, author the textbooks, and give the presentations that we absorb to become better dermatologists. KOLs have become intimately entwined with the marketing of pharmaceuticals and medical devices, used not only to lend credibility to claims of efficacy and safety but also to promote anecdotal and off-label use of these medications to increase industry profits. Identification and marketing of the KOLs themselves is being done more and more often by KOL management companies who are hired by industry to turn those involved in medical education and research into efficient and pr...</description>
            <author>Dermatologic Therapy</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2391504</comments>
            <pubDate>Wed, 06 May 2009 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">2391504</guid>        </item>
        <item>
            <title>Drug therapy in pediatrics: a developing field</title>
            <link>http://www.medworm.com/index.php?rid=2391503&amp;cid=s_31737_12_f&amp;fid=31737&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1529-8019.2009.01239.x</link>
            <description>For many years, drug therapies were not explicitly studied in the pediatric population. The lack of data forced clinicians to treat children using empiric therapy, often guessing at the treatment dose. In addition to the lack of dosing information, there was no evidence that a product would be safe and efficacious in this unique population. Because dermatologic conditions are common in children, this lack of information affected dermatologists. In 1998, a new legislation passed that encouraged drug development in pediatrics. Additional legislation followed that allowed the Food and Drug Administration the authority to require studies in pediatrics when it was anticipated that a product would be used in the pediatric population. With the new legislation and a better understanding of differe...</description>
            <author>Dermatologic Therapy</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2391503</comments>
            <pubDate>Wed, 06 May 2009 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">2391503</guid>        </item>
        <item>
            <title>Sources of drug information: FDA-approved labeling and other official FDA sources</title>
            <link>http://www.medworm.com/index.php?rid=2391502&amp;cid=s_31737_12_f&amp;fid=31737&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1529-8019.2009.01238.x</link>
            <description>To protect the public health and facilitate the safe and effective use of prescription drugs, the Food and Drug Administration (FDA) disseminates information through drug labeling, communication of safety issues, and the archiving of scientific reviews. The content and format requirements for professional labeling were revised in 2006 to improve the accessibility and usability of the information. New or emerging safety information is communicated using the formats of public health advisories (PHAs), information for heath care professional sheets, and early communications about ongoing safety reviews. The FDA analyses of approved drug marketing applications and Advisory Committee transcripts are posted on the FDA Web site. Prescribers can utilize these resources to inform the care that they...</description>
            <author>Dermatologic Therapy</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2391502</comments>
            <pubDate>Wed, 06 May 2009 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">2391502</guid>        </item>
        <item>
            <title>Medical device regulation: what a practicing dermatologist should know</title>
            <link>http://www.medworm.com/index.php?rid=2391501&amp;cid=s_31737_12_f&amp;fid=31737&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1529-8019.2009.01237.x</link>
            <description>This article is written by staff currently employed at the Center for Devices and Radiological Health and should provide information useful to the practicing dermatologist. (Source: Dermatologic Therapy)</description>
            <author>Dermatologic Therapy</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2391501</comments>
            <pubDate>Wed, 06 May 2009 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">2391501</guid>        </item>
        <item>
            <title>Generic drugs &amp;#x2013; safe, effective, and affordable</title>
            <link>http://www.medworm.com/index.php?rid=2391500&amp;cid=s_31737_12_f&amp;fid=31737&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1529-8019.2009.01236.x</link>
            <description>This article discusses the history and evolution of the process for generic drug evaluation and approval in the United States, with emphasis on locally acting dermatologic products. The requirements for in vivo bioequivalence (BE) testing and the statistical criteria for BE are discussed, and an example of a topical antifungal dermatologic product is used to demonstrate the BE determination for locally acting drugs. Other factors in the dispensing of prescription medications that are not within the Food and Drug Administration regulatory authority are also mentioned. (Source: Dermatologic Therapy)</description>
            <author>Dermatologic Therapy</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2391500</comments>
            <pubDate>Wed, 06 May 2009 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">2391500</guid>        </item>
        <item>
            <title>Considerations before choosing (extemporaneously) compounded products</title>
            <link>http://www.medworm.com/index.php?rid=2391499&amp;cid=s_31737_12_f&amp;fid=31737&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1529-8019.2009.01235.x</link>
            <description>Despite a plethora of pre-packaged topical products produced by the pharmaceutical industry for treating skin diseases, the practice of extemporaneous compounding continues, albeit at a low level ( (Source: Dermatologic Therapy)</description>
            <author>Dermatologic Therapy</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2391499</comments>
            <pubDate>Wed, 06 May 2009 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">2391499</guid>        </item>
        <item>
            <title>Drugs and other product choices</title>
            <link>http://www.medworm.com/index.php?rid=2391498&amp;cid=s_31737_12_f&amp;fid=31737&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1529-8019.2009.01234.x</link>
            <description>Dermatologists have at their disposal a wide range of products to recommend or prescribe to their patients, all of which are regulated in some way by the Food and Drug Administration (FDA). However, the degree to which FDA has confirmed the safety and efficacy of a dermatological product can vary widely. Most prescription and some over-the-counter drugs and medical devices are approved by the FDA based on scientific data. Most over-the-counter drugs are marketed in compliance with FDA regulations based on expert medical review. The FDA clears most medical devices based on their substantial equivalence to other legally marketed devices. Cosmetics, medical foods, and dietary supplements are subject only to general postmarket prohibitions against adulterated and misbranded products, although ...</description>
            <author>Dermatologic Therapy</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2391498</comments>
            <pubDate>Wed, 06 May 2009 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">2391498</guid>        </item>
        <item>
            <title>Finding, evaluating, and managing drug-related risks: approaches taken by the US Food and Drug Administration (FDA)</title>
            <link>http://www.medworm.com/index.php?rid=2391497&amp;cid=s_31737_12_f&amp;fid=31737&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1529-8019.2009.01233.x</link>
            <description>Marketed pharmaceuticals are evaluated for safety by the US Food and Drug Administration (FDA) throughout the life cycle of the products. The FDA uses data from controlled clinical trials, from postmarketing case reports reported to the FDA's Adverse Event Reporting System, from epidemiological studies, and from registries to evaluate the safety of approved products. For some products, including some products used in dermatologic medicine, risks become apparent during the postmarketing period that require additional measures beyond product labeling and routine pharmacovigilance. The FDA continues to seek additional tools to assess risk, including pharmacogenomic biomarkers for adverse drug reactions and the use of large medical record and epidemiological databases for the systematic detect...</description>
            <author>Dermatologic Therapy</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2391497</comments>
            <pubDate>Wed, 06 May 2009 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">2391497</guid>        </item>
        <item>
            <title>Clinical trials and statistical analyses: what should dermatologists look for in a report?</title>
            <link>http://www.medworm.com/index.php?rid=2391496&amp;cid=s_31737_12_f&amp;fid=31737&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1529-8019.2009.01232.x</link>
            <description>Clinicians need to evaluate the quality of individual clinical studies and synthesize the information from multiple clinical studies to provide insights in selecting appropriate therapies for patients. Understanding the key statistical principles that underlie a clinical trial and how they may be implemented can help clinicians properly interpret the efficacy and safety findings of clinical trials. Several factors should be considered when evaluating clinical studies reported in the literature, as important differences might exist among reported studies, thereby impacting the reliability of their findings. Studies vary in terms of study design, conduct, analysis, and presentation of findings. The key features to consider when evaluating clinical trials are inferential intent (exploratory v...</description>
            <author>Dermatologic Therapy</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2391496</comments>
            <pubDate>Wed, 06 May 2009 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">2391496</guid>        </item>
        <item>
            <title>Evaluating the severity of dermatologic disorders</title>
            <link>http://www.medworm.com/index.php?rid=2391495&amp;cid=s_31737_12_f&amp;fid=31737&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1529-8019.2009.01231.x</link>
            <description>Assessment of a patient's disease severity is an essential component of formulating therapeutic strategies. However, disorders of the skin are often not amenable to strict classification criteria, and the dermatologist relies upon personal thresholds of severity when assessing the patient's overall condition. A number of grading systems have arisen, primarily from the need for standardized end points in clinical trials; in some circumstances, these severity assessments may assist the clinician in the evaluation and treatment of dermatologic disease. In this review, we will summarize the results of available severity scores of frequently encountered dermatologic disorders and discuss their utility in the management of disease in a clinician's office. (Source: Dermatologic Therapy)</description>
            <author>Dermatologic Therapy</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2391495</comments>
            <pubDate>Wed, 06 May 2009 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">2391495</guid>        </item>
        <item>
            <title>Choosing dermatologic therapies</title>
            <link>http://www.medworm.com/index.php?rid=2391494&amp;cid=s_31737_12_f&amp;fid=31737&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1529-8019.2009.01230.x</link>
            <description>(Source: Dermatologic Therapy)</description>
            <author>Dermatologic Therapy</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2391494</comments>
            <pubDate>Fri, 01 May 2009 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">2391494</guid>        </item>
        <item>
            <title>Vaccines under study: non-HIV vaccines</title>
            <link>http://www.medworm.com/index.php?rid=2306479&amp;cid=s_31737_12_f&amp;fid=31737&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1529-8019.2009.01229.x</link>
            <description>This article focuses on vaccines that have yet to be approved for licensure. (Source: Dermatologic Therapy)</description>
            <author>Dermatologic Therapy</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2306479</comments>
            <pubDate>Wed, 25 Mar 2009 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">2306479</guid>        </item>
        <item>
            <title>HIV vaccines under study</title>
            <link>http://www.medworm.com/index.php?rid=2306478&amp;cid=s_31737_12_f&amp;fid=31737&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1529-8019.2009.01228.x</link>
            <description>This article will review the various current HIV vaccine candidates under study. (Source: Dermatologic Therapy)</description>
            <author>Dermatologic Therapy</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2306478</comments>
            <pubDate>Wed, 25 Mar 2009 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">2306478</guid>        </item>
        <item>
            <title>Human papillomavirus vaccines</title>
            <link>http://www.medworm.com/index.php?rid=2306477&amp;cid=s_31737_12_f&amp;fid=31737&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1529-8019.2009.01227.x</link>
            <description>Cervical and other cancers linked to the human papillomavirus (HPV) are a cause of significant morbidity and mortality. Since the discovery of HPV as a cause of these cancers, there has been much research and development in the field of HPV vaccination. Two current prophylactic vaccines have proved highly effective in preventing disease because of the vaccine types. Recent advances in prophylactic and therapeutic vaccines are discussed. (Source: Dermatologic Therapy)</description>
            <author>Dermatologic Therapy</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2306477</comments>
            <pubDate>Wed, 25 Mar 2009 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">2306477</guid>        </item>
        <item>
            <title>Varicella zoster vaccines</title>
            <link>http://www.medworm.com/index.php?rid=2306476&amp;cid=s_31737_12_f&amp;fid=31737&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1529-8019.2009.01226.x</link>
            <description>In the past, the varicella zoster virus affected virtually the entire population and had substantial morbidity and mortality associated with both primary varicella and herpes zoster reactivation. Since the varicella vaccine was first approved in 1995, there has been a significant decline in incidence, morbidity, and mortality caused by primary varicella. Breakthrough disease with the one-dose vaccine schedule led to the recommendation in 2006 that children receive a two-dose vaccine series. Older adults have also benefited from the development of the zoster vaccine. In 2006, the Food and Drug Administration approved the zoster vaccine, a higher concentration of the same live attenuated virus used in the primary varicella vaccine, for persons 60 years of age or older. It has the potential t...</description>
            <author>Dermatologic Therapy</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2306476</comments>
            <pubDate>Wed, 25 Mar 2009 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">2306476</guid>        </item>
        <item>
            <title>Existing antibacterial vaccines</title>
            <link>http://www.medworm.com/index.php?rid=2306475&amp;cid=s_31737_12_f&amp;fid=31737&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1529-8019.2009.01225.x</link>
            <description>This article will review the currently approved antibacterial vaccines, which are vaccines for pertussis, tetanus, diphtheria, meningococcus, pneumococcus, Haemophilus influenza, cholera, typhoid, and anthrax. (Source: Dermatologic Therapy)</description>
            <author>Dermatologic Therapy</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2306475</comments>
            <pubDate>Wed, 25 Mar 2009 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">2306475</guid>        </item>
        <item>
            <title>Existing antiviral vaccines</title>
            <link>http://www.medworm.com/index.php?rid=2306474&amp;cid=s_31737_12_f&amp;fid=31737&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1529-8019.2009.01224.x</link>
            <description>This article will review vaccination for the following viral diseases: measles, mumps, rubella, polio, hepatitis A, hepatitis B, influenza, rotavirus, rabies, monkeypox, smallpox, Japanese encephalitis, and yellow fever. (Source: Dermatologic Therapy)</description>
            <author>Dermatologic Therapy</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2306474</comments>
            <pubDate>Wed, 25 Mar 2009 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">2306474</guid>        </item>
        <item>
            <title>Vaccine immunology</title>
            <link>http://www.medworm.com/index.php?rid=2306473&amp;cid=s_31737_12_f&amp;fid=31737&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1529-8019.2009.01223.x</link>
            <description>This article provides a review of immunology to enhance understanding of vaccine efficacy and use, and elaborates on the immune response to vaccination. The use of vaccines to prevent infectious diseases represents a tremendous accomplishment of biomedical science, especially considering the complex interplay of the immune system with innumerable pathogens. Vaccines have allowed for total eradication of one disease and have significantly reduced the incidence of other diseases. In order to have a successful vaccine-based eradication program, the infection must be limited to humans without an animal reservoir and only one or a few strains may exist in viral infection. These strains must have constant antigenic properties. A number of vaccine types exist, both traditional and innovative, and...</description>
            <author>Dermatologic Therapy</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2306473</comments>
            <pubDate>Wed, 25 Mar 2009 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">2306473</guid>        </item>
        <item>
            <title>Safety and efficacy of vaccines</title>
            <link>http://www.medworm.com/index.php?rid=2306472&amp;cid=s_31737_12_f&amp;fid=31737&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1529-8019.2009.01222.x</link>
            <description>For the past two centuries, vaccines have provided a safe and effective means of preventing a number of infectious diseases. Although the safety of some vaccines has been questioned in recent years, the currently available vaccines are more than a millionfold safer than the diseases they are designed to prevent. Vaccines, however, should always be used in conjunction with other public health interventions. One important intervention is education because the general public can be led to believe that vaccines are unsafe and not needed by misinformation readily available electronically and in print. Not only are some vaccines available via injection but other vaccines are also given orally or intranasally. New vaccines are being studied for topical and intravaginal use. In addition, new syste...</description>
            <author>Dermatologic Therapy</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2306472</comments>
            <pubDate>Wed, 25 Mar 2009 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">2306472</guid>        </item>
        <item>
            <title>Vaccines for the prevention of infectious diseases with mucocutaneous manifestations</title>
            <link>http://www.medworm.com/index.php?rid=2306471&amp;cid=s_31737_12_f&amp;fid=31737&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1529-8019.2009.01221.x</link>
            <description>(Source: Dermatologic Therapy)</description>
            <author>Dermatologic Therapy</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2306471</comments>
            <pubDate>Sun, 01 Mar 2009 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">2306471</guid>        </item>
        <item>
            <title>Camouflage for vitiligo</title>
            <link>http://www.medworm.com/index.php?rid=2193084&amp;cid=s_31737_12_f&amp;fid=31737&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1529-8019.2008.01220.x</link>
            <description>Cosmetic camouflage is indispensable for patients with vitiligo and can result in an improvement of their quality of life. Recent cosmetic advances enabled camouflage to obtain a suitable color match and keep it waterproof. However, camouflage needs some techniques. Therefore, patient education through a camouflage lesson is required to enjoy camouflage. Here the authors introduced a few tips for suitable camouflage, which were devised through camouflage lessons. (Source: Dermatologic Therapy)</description>
            <author>Dermatologic Therapy</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2193084</comments>
            <pubDate>Tue, 17 Feb 2009 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">2193084</guid>        </item>
        <item>
            <title>Palmoplantar pustulosis treated with itraconazole: a single, active-arm pilot study</title>
            <link>http://www.medworm.com/index.php?rid=2193083&amp;cid=s_31737_12_f&amp;fid=31737&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1529-8019.2008.01219.x</link>
            <description>Pustulosis palmoplantaris (PPP; synonyms: pustulosis palmaris et plantaris, palmoplantar amicrobic pustulosis) is a common chronic, relapsing, pustular eruption affecting the palms and soles. The authors report the successful treatment of six therapy-experienced patients with histologically confirmed PPP with oral itraconazole (100 mg/day for 1 month, followed by a month of 100 mg/day every other day). Three of six patients showed complete clearance of pustules, significant reduction of erythema, and unnoticeable desquamation, whereas the other three patients had no new pustules appearing and had modest reduction of erythema and desquamation. All patients experienced relapses within a month of therapy cessation. Two of the three complete responders reinitiated itraconazole therapy at 100 m...</description>
            <author>Dermatologic Therapy</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2193083</comments>
            <pubDate>Tue, 17 Feb 2009 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">2193083</guid>        </item>
        <item>
            <title>A multicenter study of cellulite treatment with a variable emission radio frequency system</title>
            <link>http://www.medworm.com/index.php?rid=2193082&amp;cid=s_31737_12_f&amp;fid=31737&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1529-8019.2008.01218.x</link>
            <description>Radio frequency (RF) systems have been reported as producing electrothermally mediated and subcutaneous effects. The present study evaluates a new approach to treat cellulite with a bipolar RF device. The buttocks of 50 patients were treated, 10 from each of five multinational centers with a novel bipolar RF technology set at 6 J/cm3, which changes its frequency between 0.6 and 2.4 MHz according to impedance of tissue. Twelve weekly sessions were given for 12 minutes on each buttock, with a treatment end point of 42°C external skin temperature. Cellulite changes and tissue condition were assessed before and immediately after the first session, before the final 12th session, and 2 months thereafter. The patient Satisfaction Index was recorded. Objective evaluation involved clinical photogr...</description>
            <author>Dermatologic Therapy</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2193082</comments>
            <pubDate>Tue, 17 Feb 2009 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">2193082</guid>        </item>
        <item>
            <title>Effects of tumor necrosis factor-&amp;#x03B1; blockade on metabolic syndrome components in psoriasis and psoriatic arthritis and additional lessons learned from rheumatoid arthritis</title>
            <link>http://www.medworm.com/index.php?rid=2193081&amp;cid=s_31737_12_f&amp;fid=31737&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1529-8019.2008.01217.x</link>
            <description>Psoriasis (PsO) and psoriatic arthritis (PsA) are chronic T cell-mediated inflammatory diseases that manifest not only in the skin and joints but also in the form of cardiometabolic disturbances, which include insulin resistance, dyslipidemia, and obesity. Thus, PsO and PsA patients are predisposed to metabolic syndrome (MetS), diabetes, and cardiovascular disease. In recent years, the introduction of targeted therapy in the form of tumor necrosis factor-[alpha] (TNF-[alpha]) antagonists, such as infliximab, etanercept, and adalimumab has been an important and effective addition to the treatment armamentarium for PsO and PsA. Although TNF-[alpha] antagonists have produced promising results clinically in reducing cutaneous and joint manifestations of PsO and PsA, their effects on MetS compo...</description>
            <author>Dermatologic Therapy</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2193081</comments>
            <pubDate>Tue, 17 Feb 2009 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">2193081</guid>        </item>
        <item>
            <title>New biologics for psoriasis and psoriatic arthritis</title>
            <link>http://www.medworm.com/index.php?rid=2193080&amp;cid=s_31737_12_f&amp;fid=31737&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1529-8019.2008.01216.x</link>
            <description>The prevalence of psoriasis is estimated to be 2.2% in the United States, and 6[ndash]39% of patients with psoriasis also develop psoriatic arthritis. New advances have been made in developing treatment options. A new human tumor necrosis factor (TNF)-[alpha] antibody, golimumab, has been shown to significantly improve symptoms of psoriatic arthritis. In addition, clinical trials of certolizumab pegol, a PEGylated Fab' fragment of an anti-TNF-[alpha] monoclonal antibody, show promising results for treating rheumatoid arthritis and suggest that it may be applicable for treating psoriasis and psoriatic arthritis in the future. New biologic therapies also include antibodies to interleukin-12 and interleukin-23. Phase II studies suggest that ustekinumab is effective in alleviating symptoms of ...</description>
            <author>Dermatologic Therapy</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2193080</comments>
            <pubDate>Tue, 17 Feb 2009 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">2193080</guid>        </item>
        <item>
            <title>Psoriatic arthritis</title>
            <link>http://www.medworm.com/index.php?rid=2193079&amp;cid=s_31737_12_f&amp;fid=31737&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1529-8019.2008.01215.x</link>
            <description>Although there is still some controversy about the existence of psoriatic arthritis (PsA) as a specific form of inflammatory arthritis associated with psoriasis, epidemiological and clinical studies support the unique features of PsA. Because of lack of diagnostic or classification criteria, the disease has been thought of as uncommon. New classification criteria should facilitate case definition of PsA. Over the past several decades, it has become clear that the disease leads to serious disability and even increased mortality. Traditional medications have not been effective in preventing the progression of joint damage. New medications, including biologics, have emerged with potential to controlling the inflammation and arresting the progression of joint damage. (Source: Dermatologic Ther...</description>
            <author>Dermatologic Therapy</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2193079</comments>
            <pubDate>Tue, 17 Feb 2009 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">2193079</guid>        </item>
        <item>
            <title>Pediatric psoriasis: updates in biologic therapies</title>
            <link>http://www.medworm.com/index.php?rid=2193078&amp;cid=s_31737_12_f&amp;fid=31737&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1529-8019.2008.01214.x</link>
            <description>Psoriasis is not a rare disease in the pediatric population. Early recognition and treatment is necessary to improve the physical and psychological symptoms of psoriasis and minimize its adverse effects on future health. In moderate-to-severe cases, treatment is challenging. There is no Food and Drug Administration (FDA)-approved systemic treatment for children and adolescents with moderate-to-severe plaque-type psoriasis other than topical corticosteroids, and current treatment is limited to the ones that are used in adults, which may have more severe side effects in children. Recently, there have been advances in the use of biologic therapies, specifically tumor necrosis factor (TNF)-alpha blockers, for pediatric autoimmune diseases and pediatric psoriasis. The present review will summar...</description>
            <author>Dermatologic Therapy</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2193078</comments>
            <pubDate>Tue, 17 Feb 2009 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">2193078</guid>        </item>
        <item>
            <title>Long-term efficacy of biologics in dermatology</title>
            <link>http://www.medworm.com/index.php?rid=2193077&amp;cid=s_31737_12_f&amp;fid=31737&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1529-8019.2008.01213.x</link>
            <description>Chronic dermatologic diseases affect millions of people. The long-term nature of these diseases creates psychological and financial burden as well as substantially impacts patients' quality of life. Biologics, including adalimumab, etanercept, alefacept, efalizumab, and infliximab, are the newest therapeutic agents in the treatment of moderate-to-severe psoriasis and psoriatic arthritis and have been used in a variety of other dermatologic diseases. These agents act relatively quickly and effectively in 12-week clinical trials. Because these agents are used to treat patients for longer than 12 weeks, there is a need to review the safety and efficacy of these agents over longer periods of time. Many levels of evidence are available for biologics including high level of evidence from large, ...</description>
            <author>Dermatologic Therapy</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2193077</comments>
            <pubDate>Tue, 17 Feb 2009 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">2193077</guid>        </item>
        <item>
            <title>Long-term safety of biologics in dermatology</title>
            <link>http://www.medworm.com/index.php?rid=2193076&amp;cid=s_31737_12_f&amp;fid=31737&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1529-8019.2008.01212.x</link>
            <description>The use of biologics in dermatology has increased rapidly. Although most are relatively safe when correctly used and monitored, there are known side effects and adverse events that occur. Selection of patients should be done on a case-by-case basis. Severity of disease, comorbidity profile, drug profile, and cost-effectiveness should be all taken into consideration while deciding to start and/or maintain one of these therapies. Dermatologists should be aware of the benefits and limitations of this class of drugs, as well as the appropriate monitoring. The authors propose a concise overview of the safety profiles of some of the biologics currently used in the dermatologic field. (Source: Dermatologic Therapy)</description>
            <author>Dermatologic Therapy</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2193076</comments>
            <pubDate>Tue, 17 Feb 2009 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">2193076</guid>        </item>
        <item>
            <title>Introduction</title>
            <link>http://www.medworm.com/index.php?rid=2193075&amp;cid=s_31737_12_f&amp;fid=31737&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1529-8019.2008.01211.x</link>
            <description>(Source: Dermatologic Therapy)</description>
            <author>Dermatologic Therapy</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2193075</comments>
            <pubDate>Thu, 01 Jan 2009 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">2193075</guid>        </item>
        <item>
            <title>Sebaceous carcinoma: the great masquerader</title>
            <link>http://www.medworm.com/index.php?rid=2024036&amp;cid=s_31737_12_f&amp;fid=31737&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1529-8019.2008.00247.x</link>
            <description>ABSTRACT: Sebaceous carcinoma (SC) is a rare tumor with a high rate of local recurrence and metastasis to lymph nodes and organs. The majority of SCs occur in the periocular region frequently presenting as painless, round subcutaneous nodules with a high tendency of diffuse and invasive growth in the eyelid and conjunctiva. It frequently masquerades as inflammatory conditions or as other tumors leading to delay in diagnosis, inappropriate treatment and increased morbidity and mortality. Sebaceous carcinoma is associated with Muir[ndash]Torre syndrome, a genetic condition presenting with sebaceous skin tumors associated with internal malignancy. Therefore, SC patients must be carefully evaluated and referred to an internist or gastroenterologist when indicated. Surgery is the definitive the...</description>
            <author>Dermatologic Therapy</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2024036</comments>
            <pubDate>Mon, 08 Dec 2008 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">2024036</guid>        </item>
        <item>
            <title>Microcystic adnexal carcinoma: a diagnostic and therapeutic challenge</title>
            <link>http://www.medworm.com/index.php?rid=2024035&amp;cid=s_31737_12_f&amp;fid=31737&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1529-8019.2008.00246.x</link>
            <description>ABSTRACT: Microcystic adnexal carcinoma (MAC) is a rare cutaneous neoplasm that is often diagnosed after having been present for a significant period of time. It appears bland on histologic evaluation despite its locally aggressive behavior. Actual skin involvement is significantly more extensive than can be determined clinically and because of this, therapy is challenging. Though metastasis is rare, there have been reports of both regional and distant metastatic disease. Several treatment modalities have been used to date, including standard excision (SE), Mohs micrographic surgery (MMS), irradiation, chemotherapy, and observation. There has also been discussion in the literature regarding techniques than can aid in assurance of clear margins with MMS. We review the literature on MAC, inc...</description>
            <author>Dermatologic Therapy</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2024035</comments>
            <pubDate>Mon, 08 Dec 2008 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">2024035</guid>        </item>
        <item>
            <title>Merkel cell carcinoma</title>
            <link>http://www.medworm.com/index.php?rid=2024034&amp;cid=s_31737_12_f&amp;fid=31737&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1529-8019.2008.00245.x</link>
            <description>ABSTRACT: Merkel cell carcinoma is a rare cutaneous malignancy that occurs mainly in the ultraviolet-exposed areas of the head and neck region and has a mortality rate higher than that of melanoma (33%) with a tendency to recur. The clinical features, diagnosis, work up, and current recommendations for treatment of Merkel cell carcinoma are discussed. (Source: Dermatologic Therapy)</description>
            <author>Dermatologic Therapy</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2024034</comments>
            <pubDate>Mon, 08 Dec 2008 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">2024034</guid>        </item>
        <item>
            <title>Lentigo maligna</title>
            <link>http://www.medworm.com/index.php?rid=2024033&amp;cid=s_31737_12_f&amp;fid=31737&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1529-8019.2008.00244.x</link>
            <description>ABSTRACT: Lentigo maligna (LM), a melanoma in situ, is a fairly common melanocytic lesion that usually develops on the chronically sun-exposed skin of the head and neck of Caucasians. It occurs mostly in people older than 40 years, with an incidence rate that increases with age and peaks in the seventh and eighth decades of life. Its diagnosis and treatment remain challenging. In this article, we review the history, epidemiology, clinical presentation, histology, and treatment of LM. (Source: Dermatologic Therapy)</description>
            <author>Dermatologic Therapy</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2024033</comments>
            <pubDate>Mon, 08 Dec 2008 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">2024033</guid>        </item>
        <item>
            <title>Eccrine porocarcinoma</title>
            <link>http://www.medworm.com/index.php?rid=2024032&amp;cid=s_31737_12_f&amp;fid=31737&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1529-8019.2008.00243.x</link>
            <description>ABSTRACT: Eccrine porocarcinoma (EPC) is a rare cutaneous neoplasm that grows slowly over a long period of time but often experiences an accelerated growth phase. This malignant tumor may arise denovo or evolve from a pre-existing benign eccrine poroma. Histologic evaluation demonstrates anaplastic cells involving the epidermis and infiltrating the dermis. Metastasis to regional lymph nodes distally occurs in a significant number of cases. Treatment modalities have included standard excision, Mohs micrographic surgery (MMS), chemotherapy, and radiation therapy. Recently sentinel lymph node biopsy has begun to be investigated as a staging tool. The literature on EPC is reviewed with attention paid to which of the various therapeutic options offers a clear advantage over the others. MMS affo...</description>
            <author>Dermatologic Therapy</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2024032</comments>
            <pubDate>Mon, 08 Dec 2008 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">2024032</guid>        </item>
        <item>
            <title>Dermatofibrosarcoma protuberans</title>
            <link>http://www.medworm.com/index.php?rid=2024031&amp;cid=s_31737_12_f&amp;fid=31737&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1529-8019.2008.00242.x</link>
            <description>ABSTRACT: Dermatofibrosarcoma protuberans is a rare cutaneous malignancy that is locally invasive, occurs mainly over the trunk and proximal extremities, and has a tendency to recur after wide local excision. The epidemiology, clinical features, diagnosis, histology, and treatment options are discussed. (Source: Dermatologic Therapy)</description>
            <author>Dermatologic Therapy</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2024031</comments>
            <pubDate>Mon, 08 Dec 2008 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">2024031</guid>        </item>
        <item>
            <title>Atypical fibroxanthoma/malignant fibrous histiocytoma</title>
            <link>http://www.medworm.com/index.php?rid=2024030&amp;cid=s_31737_12_f&amp;fid=31737&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1529-8019.2008.00241.x</link>
            <description>ABSTRACT: Atypical fibroxanthoma (AFX) is an unusual spindle cell tumor occurring on actinically damaged skin of the head and neck. Clinically, it is often confused with basal cell carcinoma, squamous cell carcinoma, or even melanoma. Although initially thought to be a diagnosis of exclusion histologically, newer immunostains have helped in the identification of AFX. Mohs micrographic surgery has been utilized for the treatment due to its tissue sparing ability along with lower recurrence rate. (Source: Dermatologic Therapy)</description>
            <author>Dermatologic Therapy</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2024030</comments>
            <pubDate>Mon, 08 Dec 2008 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">2024030</guid>        </item>
        <item>
            <title>Introduction</title>
            <link>http://www.medworm.com/index.php?rid=2024029&amp;cid=s_31737_12_f&amp;fid=31737&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1529-8019.2008.00240.x</link>
            <description>(Source: Dermatologic Therapy)</description>
            <author>Dermatologic Therapy</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2024029</comments>
            <pubDate>Sat, 01 Nov 2008 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">2024029</guid>        </item>
        <item>
            <title>Benefits of an emollient body wash for patients with chronic winter dry skin</title>
            <link>http://www.medworm.com/index.php?rid=1858112&amp;cid=s_31737_12_f&amp;fid=31737&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1529-8019.2008.00225.x</link>
            <description>ABSTRACT: This randomized 5-week study assessed the clinical benefits of a high-emollient body wash versus a regular bar cleanser in terms of improving chronic winter dry skin condition. After 4 weeks, subjects who washed daily with a high-emollient body wash exhibited a significant reduction in all dermatologist-assessed dry skin attributes and improvements in self-evaluated skin condition when compared with baseline measures. Those subjects who washed with a regular bar cleanser experienced a minimal to marked increase in dermatologist-assessed and self-assessed dry skin attributes when compared with baseline. These findings suggested that bathing with a high-emollient body wash, as opposed to a regular bar cleanser, can reduce xerosis symptoms and improve skin health and appearance with...</description>
            <author>Dermatologic Therapy</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1858112</comments>
            <pubDate>Mon, 06 Oct 2008 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">1858112</guid>        </item>
        <item>
            <title>Photodynamic therapy: treatment of choice for actinic cheilitis?</title>
            <link>http://www.medworm.com/index.php?rid=1858111&amp;cid=s_31737_12_f&amp;fid=31737&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1529-8019.2008.00224.x</link>
            <description>ABSTRACT: The major therapeutic approaches (5-fluorouracil, imiquimod, vermilionectomy, and CO2 Laser ablation) for actinic cheilitis are aimed at avoiding and preventing a malignant transformation into invasive squamous cell carcinoma via destruction/removal of the damaged epithelium. Recently, photodynamic therapy (PDT) has been introduced as a therapeutic modality for epithelial skin tumors, with good efficacy/safety profile and good cosmetic results. Regarding actinic cheilitis, PDT could be considered a new therapeutic option? The target of our study was to evaluate the efficacy and tolerability of PDT in actinic cheilitis, using a methyl-ester of aminolevulinic acid (MAL) as topical photosensitizing agent and controlled the effects of the therapy for a 30-month follow-up period. MAL-...</description>
            <author>Dermatologic Therapy</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1858111</comments>
            <pubDate>Mon, 06 Oct 2008 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">1858111</guid>        </item>
        <item>
            <title>Indications for psychological intervention in patients with psoriasis</title>
            <link>http://www.medworm.com/index.php?rid=1858110&amp;cid=s_31737_12_f&amp;fid=31737&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1529-8019.2008.00223.x</link>
            <description>ABSTRACT: Various forms of psychological interventions have since long been proposed as potentially helpful adjuncts to standard pharmacological therapy of psoriasis. All studies investigating the effectiveness of psychological intervention in psoriasis reported its positive impact on the patients' psychological well-being and some studies also reported improvements in the skin condition as a result of psychotherapy. When making a decision about the referral of a given patient to the psychologist, both clinical (psoriasis-specific) and general (psychotherapy-specific) indications should be taken into consideration. This can allow a better identification of those psoriasis patients who are in real need for psychological intervention and who are most likely to benefit from it. (Source: Derma...</description>
            <author>Dermatologic Therapy</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1858110</comments>
            <pubDate>Mon, 06 Oct 2008 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">1858110</guid>        </item>
        <item>
            <title>A medical alternative to the treatment of compensatory sweating</title>
            <link>http://www.medworm.com/index.php?rid=1858109&amp;cid=s_31737_12_f&amp;fid=31737&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1529-8019.2008.00222.x</link>
            <description>ABSTRACT: Compensatory sweating after sympathectomy does not have a satisfactory, free-of-secondary-effects treatment. Glycopyrrolate has been successfully used to treat other types of hyperhidrosis. Compensatory sweating after sympathectomy could respond to the topical application of glycopyrrolate. Ten patients were selected with compensatory sweating after sympathectomy. One milliliter of a 2% water solution of topical glycopyrrolate was applied once a day over the affected area and massaged for 30 seconds. Treatment was maintained for 6 weeks. The results were rated using a scale from 1 to 10 of satisfaction at the end of the study. Eight of the 10 treated patients dramatically improved with the topical application of glycopyrrolate. Two patients quit the treatment due to secondary eff...</description>
            <author>Dermatologic Therapy</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1858109</comments>
            <pubDate>Mon, 06 Oct 2008 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">1858109</guid>        </item>
        <item>
            <title>Vascular based non conventional dye laser treatment for basal cell carcinoma</title>
            <link>http://www.medworm.com/index.php?rid=1858108&amp;cid=s_31737_12_f&amp;fid=31737&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1529-8019.2008.00221.x</link>
            <description>ABSTRACT: Basal cell carcinoma is the most common skin tumor in humans which can be removed in a variety of ways (depending on the type of the lesion, the affected area, and depth of the lesion). Laser therapy offers another option to the traditional methods of treatment; thus, the purpose of this work is to valuate the efficacy of dye laser in a selected group of patients affected by superficial basal cell carcinoma. We suggest that the success of pulse dye laser treatment lies in the fact that as all tumors, basal cell carcinomas contain an increased number of dilated blood vessels. Twenty patients (eight males and 12 females) with superficial basal cell carcinoma were given five treatments with a flashlamp-pumped pulse dye laser every 20 days. The clinical follow up was 12[ndash]24 mont...</description>
            <author>Dermatologic Therapy</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1858108</comments>
            <pubDate>Mon, 06 Oct 2008 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">1858108</guid>        </item>
        <item>
            <title>Physical means of treating unwanted hair</title>
            <link>http://www.medworm.com/index.php?rid=1858107&amp;cid=s_31737_12_f&amp;fid=31737&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1529-8019.2008.00220.x</link>
            <description>ABSTRACT: Unwanted facial and body hair is a common problem, generating a high level of interest for treatment innovations. A wide range of modalities for the management of unwanted hair have been advocated over the years with varying degrees of clinical success. Most recently, lasers and light sources have been used to address this problem with improved clinical success rates in properly selected patients. The full range of temporary and permanent hair removal techniques will be outlined in this review of physical means of treating unwanted hair. (Source: Dermatologic Therapy)</description>
            <author>Dermatologic Therapy</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1858107</comments>
            <pubDate>Mon, 06 Oct 2008 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">1858107</guid>        </item>
        <item>
            <title>The clinical evaluation of hirsutism</title>
            <link>http://www.medworm.com/index.php?rid=1858106&amp;cid=s_31737_12_f&amp;fid=31737&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1529-8019.2008.00219.x</link>
            <description>ABSTRACT: Hirsutism is a disorder of excess growth of terminal hairs in androgen-dependent areas in women. Other cutaneous conditions associated with androgen excess are androgenetic alopecia, acanthosis nigricans, and acne. Hirsutism is often associated with measurably elevated androgen levels, but not in all cases. Androgens in women arise from the ovary and adrenal glands, and peripherally from skin and fat. The most common cause of hirsutism is polycystic ovarian syndrome. Patients with &quot;idiopathic&quot; hirsutism have normal ovulatory cycles and androgen levels. Other causes are late onset congenital adrenal hyperplasia, Cushing's syndrome, and the HAIR-AN syndrome. Pituitary, ovarian, and adrenal tumors are important, but rare causes of hirsutism. A thorough history and examination are im...</description>
            <author>Dermatologic Therapy</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1858106</comments>
            <pubDate>Mon, 06 Oct 2008 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">1858106</guid>        </item>
        <item>
            <title>Metabolic syndrome</title>
            <link>http://www.medworm.com/index.php?rid=1858105&amp;cid=s_31737_12_f&amp;fid=31737&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1529-8019.2008.00218.x</link>
            <description>ABSTRACT: Hirsutism is a finding that can lead to subsequent metabolic diagnoses such as the metabolic syndrome. Metabolic syndrome describes a cluster of cardiometabolic risk factors associated with overweight and obesity. Although it has been the subject of some controversy, perhaps due to the many definitions proposed by different health organizations, metabolic syndrome is clinically relevant in that it is a predictor of vascular risk, even independent of any associated type 2 diabetes. While various definitions may differ in precise cut-off points, they uniformly emphasize key pathophysiologic processes: visceral obesity, dyslipidemia, insulin resistance, and hypertension. Management of metabolic syndrome focuses on methods of reducing the component risk factors, and therapies thus ta...</description>
            <author>Dermatologic Therapy</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1858105</comments>
            <pubDate>Mon, 06 Oct 2008 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">1858105</guid>        </item>
        <item>
            <title>What every physician should know about polycystic ovary syndrome</title>
            <link>http://www.medworm.com/index.php?rid=1858104&amp;cid=s_31737_12_f&amp;fid=31737&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1529-8019.2008.00217.x</link>
            <description>ABSTRACT: Polycystic ovary syndrome (PCOS) is the most common endocrine cause of hirsutism, acne, and pattern alopecia. It is a heterogeneous syndrome of hyperandrogenic anovulation that is typically due to intrinsic ovarian dysfunction, which is often aggravated by insulin-resistant hyperinsulinemia with its risks of diabetes mellitus and metabolic syndrome and their complications. Because there are many pitfalls to androgen assays, evaluation for hyperandrogenemia is suggested in women with moderate or severe hirsutism or hirsutism equivalents, menstrual irregularity, acanthosis nigricans, or intractable obesity. An endocrinologic work-up is necessary to rule out other hyperandrogenic disorders that require specific therapy (e.g., virilizing tumors, nonclassic congenital adrenal hyperpla...</description>
            <author>Dermatologic Therapy</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1858104</comments>
            <pubDate>Mon, 06 Oct 2008 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">1858104</guid>        </item>
        <item>
            <title>Congenital adrenal hyperplasia</title>
            <link>http://www.medworm.com/index.php?rid=1858103&amp;cid=s_31737_12_f&amp;fid=31737&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1529-8019.2008.00216.x</link>
            <description>ABSTRACT: The congenital adrenal hyperplasias are a group of autosomal recessive disorders associated with impaired steroidogenesis. Several types of the congenital adrenal hyperplasias are associated with decreased cortisol production and excessive adrenal sex steroid secretion. Congenital adrenal hyperplasia due to 21-hydroxylase deficiency is the most common and prototypic example of this group of disorders. Herein, we review the clinical features, pathophysiology, molecular genetics, and treatment of 21-hydroxylase deficiency. There is also a brief discussion of other steroidogenic enzyme defects that are associated with clinical features due to excessive androgen secretion. (Source: Dermatologic Therapy)</description>
            <author>Dermatologic Therapy</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1858103</comments>
            <pubDate>Mon, 06 Oct 2008 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">1858103</guid>        </item>
        <item>
            <title>Medical treatment of hirsutism</title>
            <link>http://www.medworm.com/index.php?rid=1858102&amp;cid=s_31737_12_f&amp;fid=31737&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1529-8019.2008.00215.x</link>
            <description>ABSTRACT: Hirsutism is usually the result of an underlying adrenal, ovarian, or central endocrine abnormality mainly due to polycystic ovary syndrome but may also be idiopathic or drug induced. The aim of medical treatment of hirsutism is to rectify any causal hormonal balance, slow down or stop excessive hair growth, and improve the aesthetic appearance of hirsutism, thereby positively affecting the patient's quality of life. Today, for the majority of women, a monotherapy with oral contraceptives that have antiandrogenic activity is recommended as a first-line treatment for hirsutism. Combining an oral contraceptive pill with an antiandrogen is recommended if clinical improvement of hirsutism is insufficient after 6[ndash]9 months' monotherapy. In women who present with hirsutism, hypera...</description>
            <author>Dermatologic Therapy</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1858102</comments>
            <pubDate>Mon, 06 Oct 2008 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">1858102</guid>        </item>
        <item>
            <title>Androgens and hair growth</title>
            <link>http://www.medworm.com/index.php?rid=1858101&amp;cid=s_31737_12_f&amp;fid=31737&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1529-8019.2008.00214.x</link>
            <description>ABSTRACT: Hair's importance in human communication means that abnormalities like excess hair in hirsutism or hair loss in alopecia cause psychological distress. Androgens are the main regulator of human hair follicles, changing small vellus follicles producing tiny, virtually invisible hairs into larger intermediate and terminal follicles making bigger, pigmented hairs. The response to androgens varies with the body site as it is specific to the hair follicle itself. Normally around puberty, androgens stimulate axillary and pubic hair in both sexes, plus the beard, etc. in men, while later they may also inhibit scalp hair growth causing androgenetic alopecia. Androgens act within the follicle to alter the mesenchyme[ndash]epithelial cell interactions, changing the length of time the hair i...</description>
            <author>Dermatologic Therapy</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1858101</comments>
            <pubDate>Mon, 06 Oct 2008 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">1858101</guid>        </item>
        <item>
            <title>Rosaceiform eruption induced by erlotinib</title>
            <link>http://www.medworm.com/index.php?rid=1842892&amp;cid=s_31737_12_f&amp;fid=31737&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1529-8019.2008.00233.x</link>
            <description>ABSTRACT: Adverse events with anti-epidermal growth factor receptor therapy mainly involve the skin. The most common cutaneous adverse event is an acneiform eruption, which occurs in more than 50% of cases. The aim of this paper is to report the case of rosaceiform eruption induced by erlotinib in an 81-year-old-man and to discuss the pathogenetic role of Demodex folliculorum mites, found in the present patient, using skin scraping. (Source: Dermatologic Therapy)</description>
            <author>Dermatologic Therapy</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1842892</comments>
            <pubDate>Wed, 01 Oct 2008 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">1842892</guid>        </item>
        <item>
            <title>Preliminary communication: imiquimod in mixed capillary/lymphatic malformation</title>
            <link>http://www.medworm.com/index.php?rid=1842891&amp;cid=s_31737_12_f&amp;fid=31737&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1529-8019.2008.00232.x</link>
            <description>The objective of this study is to estimate the exact mechanism of action of topical imiquimod on mixed capillary/lymphatic malformation. After 4 weeks of therapy the lesions were less protuberant. At the follow-up examination after a further 2 months of therapy, there was partial clinical regression of the capillary component with a return to normal skin color. One month after termination of therapy the lesions had completely regressed and there was no evidence of recurrence of the hemangiomatous section. The present authors' case suggests the efficacy of the use of topical imiquimod and this therapeutic modality may be of particular benefit in superficial type of capillary/lymphatic malformation, in which the destructive intervention may be undesirable. (Source: Dermatologic Therapy)</description>
            <author>Dermatologic Therapy</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1842891</comments>
            <pubDate>Wed, 01 Oct 2008 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">1842891</guid>        </item>
        <item>
            <title>Sensitizing potential of triclosan and triclosan-based skin care products in patients with chronic eczema</title>
            <link>http://www.medworm.com/index.php?rid=1842890&amp;cid=s_31737_12_f&amp;fid=31737&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1529-8019.2008.00231.x</link>
            <description>ABSTRACT: Triclosan is a lypophilic chlorophenol biocide with broad-spectrum antibacterial and antifungal activity. Triclosan-based topical products have been shown to be tolerated and beneficial in atopic dermatitis. The aim of this study was to evaluate the sensitizing potential of triclosan and triclosan-based creams in patients affected by eczematous dermatitis. Two hundred and seventy-five patients affected by chronic eczema (allergic contact dermatitis, irritant contact dermatitis, atopic eczema, nummular eczema, stasis dermatitis) were patch tested with standard patch test series as well as triclosan and triclosan-based products. Standard patch test series resulted positive in 164 patients (61%), with nickel sulfate, house dust mites, fragrance mix, propolis, thimerosal, myroxylon p...</description>
            <author>Dermatologic Therapy</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1842890</comments>
            <pubDate>Wed, 01 Oct 2008 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">1842890</guid>        </item>
        <item>
            <title>Bullous skin eruption in an HIV patient during antiretroviral drugs therapy</title>
            <link>http://www.medworm.com/index.php?rid=1842889&amp;cid=s_31737_12_f&amp;fid=31737&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1529-8019.2008.00230.x</link>
            <description>ABSTRACT: Dermo-epidermal blistering is an uncommon presentation of adverse drug reactions. Several drugs are associated to such eruptions, but review of current knowledge does not list antiretroviral drugs. A 37-year-old Caucasian HIV-positive woman presented with a 6-week history of diffuse annular blistering affecting the trunk and limbs. Lesions appeared both on erythematous and normal-appearing skin. The patient was in treatment with antiretroviral (lamivudine + didanosine + nelfinavir) for 2 years. A history of previous adverse reactions to betalactams, nonsteroidal anti-inflammatory drugs, and a nevirapine-induced hepatitis was also referred. Histopathology showed a dermo[ndash]epidermal blister; direct immunofluorescence was positive for IgG, C3c at the basement membrane zone; enzy...</description>
            <author>Dermatologic Therapy</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1842889</comments>
            <pubDate>Wed, 01 Oct 2008 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">1842889</guid>        </item>
        <item>
            <title>Efalizumab in the treatment of psoriasis: when comorbidity is an issue</title>
            <link>http://www.medworm.com/index.php?rid=1842888&amp;cid=s_31737_12_f&amp;fid=31737&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1529-8019.2008.00229.x</link>
            <description>ABSTRACT: Psoriasis is a common dermatosis affecting the skin, mucosal surfaces, and cutaneous adnexa, and joints and bones can be involved at some degree in the clinical features of the disease, configuring psoriatic arthritis. Moderate to severe psoriasis has a high impact on quality of life and requires an integrated and long-term treatment schedule. However, management of psoriasis in patients affected by other systemic diseases can be challenging because of the possible side effects or contraindications of various treatments in accordance with patients' medical history. In recent times, the therapeutical approaches have changed a lot, thanks to biologicals. The current authors present some cases of psoriatic patients with comorbidities successfully treated with efalizumab, an anti-T l...</description>
            <author>Dermatologic Therapy</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1842888</comments>
            <pubDate>Wed, 01 Oct 2008 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">1842888</guid>        </item>
        <item>
            <title>Contribution of neuroinflammation in burning mouth syndrome: indications from benzodiazepine use</title>
            <link>http://www.medworm.com/index.php?rid=1842887&amp;cid=s_31737_12_f&amp;fid=31737&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1529-8019.2008.00228.x</link>
            <description>The objective of this study is to define the possible reasons for the efficacy of benzodiazepines in the treatment of the burning mouth syndrome. Starting from the report of eight cases successfully treated with prazepam, the present authors examined the clinical features and the evidence from literature that support the possibility of a role of neuroinflammation in the pathogenesis of the burning mouth syndrome. Available data suggest that the nervous system could be crucial in the pathogenesis of the syndrome (altered perception of pain, disturbance of neural transmission, increased excitability, negative involvement of trigeminal-vascular system), and the present authors' experience lets them suppose a role for neuroinflammation. This hypothesis could also explain the positive response ...</description>
            <author>Dermatologic Therapy</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1842887</comments>
            <pubDate>Wed, 01 Oct 2008 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">1842887</guid>        </item>
        <item>
            <title>Adalimumab for treatment of moderate to severe psoriasis and psoriatic arthritis</title>
            <link>http://www.medworm.com/index.php?rid=1842886&amp;cid=s_31737_12_f&amp;fid=31737&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1529-8019.2008.00227.x</link>
            <description>The objective of this study was to assess the efficacy and safety of adalimumab, a fully human antitumor necrosis factor (anti-TNF) monoclonal antibody, over 16 weeks. The present authors report their personal experience in 15 patients with severe plaque psoriasis and psoriatic arthritis, refractory to other treatments, in which a decisive regression of joint/skin involvement was obtained. Psoriasis and psoriatic arthritis are chronic inflammatory disorders resulting from a combination of genetic and environmental factors. (Source: Dermatologic Therapy)</description>
            <author>Dermatologic Therapy</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1842886</comments>
            <pubDate>Wed, 01 Oct 2008 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">1842886</guid>        </item>
        <item>
            <title>Etanercept provides a more physiological approach in the treatment of psoriasis</title>
            <link>http://www.medworm.com/index.php?rid=1842885&amp;cid=s_31737_12_f&amp;fid=31737&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1529-8019.2008.00226.x</link>
            <description>ABSTRACT: Psoriasis is a common chronic inflammatory disease affecting the skin and joints. Moderate to severe psoriasis is traditionally treated with systemic treatments, which can be effective but are often associated with relevant adverse effects, even when administered intermittently or rotationally. Biologic therapies may provide high and consistent efficacy over time, long-term safety, and simple administration schedules compared with nonbiologic therapies, and can be used in patients intolerant and/or resistant to these therapies. TNF-antagonists have a definite advantage over other biologic agents (e.g., T-cell targeting drugs) in the early and late manifestations of joint involvement. TNF-antagonists are a class of drugs with distinct pharmacokinetic and pharmacodynamic properties...</description>
            <author>Dermatologic Therapy</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1842885</comments>
            <pubDate>Mon, 01 Sep 2008 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">1842885</guid>        </item>
        <item>
            <title>The surgical treatment of cicatricial alopecia</title>
            <link>http://www.medworm.com/index.php?rid=1629565&amp;cid=s_31737_12_f&amp;fid=31737&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1529-8019.2008.00211.x</link>
            <description>ABSTRACT: Surgical correction of cicatricial alopecia can yield exceptional results when performed in the appropriate clinical scenario. To facilitate determination of the most suitable corrective therapy, we propose two new categories of cicatricial alopecia: &quot;unstable&quot; and &quot;stable.&quot; Unstable cicatricial alopecia is intermittent and results in possible subsequent scarring hair loss in either new or old areas. Stable cicatricial alopecia, on the other hand, refers to fixed permanent scarring. While surgical excision is preferred to hair transplantation for both categories of cicatricial alopecia, this preference is even stronger in cases of unstable cicatricial alopecia due to its intermittent and progressive nature. Regardless of which corrective technique is used, analysis of specific ph...</description>
            <author>Dermatologic Therapy</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1629565</comments>
            <pubDate>Tue, 15 Jul 2008 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">1629565</guid>        </item>
        <item>
            <title>Secondary cicatricial and other permanent alopecias</title>
            <link>http://www.medworm.com/index.php?rid=1629564&amp;cid=s_31737_12_f&amp;fid=31737&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1529-8019.2008.00210.x</link>
            <description>ABSTRACT: Various nonfollicular scalp conditions can cause secondary scarring or permanent alopecia. Possible causes are congenital defects, trauma, inflammatory conditions, infections, and neoplasms (rarely drugs). Associated signs and symptoms and other diagnostic procedures such as histopathology may aid in the diagnosis. Detection of the underlying disorder may be difficult in end-stage lesions. Treatment is specific for active conditions. Surgery and hair transplantation are options for localized scars. (Source: Dermatologic Therapy)</description>
            <author>Dermatologic Therapy</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1629564</comments>
            <pubDate>Tue, 15 Jul 2008 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">1629564</guid>        </item>
        <item>
            <title>Central centrifugal cicatricial alopecia</title>
            <link>http://www.medworm.com/index.php?rid=1629563&amp;cid=s_31737_12_f&amp;fid=31737&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1529-8019.2008.00209.x</link>
            <description>ABSTRACT: A progressive scarring alopecia of the central scalp is commonly seen in young to middle-aged females of African descent. It usually starts at the vertex or mid top of the scalp and gradually spreads centrifugally, hence, the unifying term of central centrifugal cicatricial alopecia. The clinical pattern is suggestive of female pattern alopecia, but a lack of follicular pores indicative of scarring is present. It can progress for years before slowly burning out. The etiology is unknown but genetic factors may be important. It is often associated with a history of traumatic hairstyling involving heat, traction, and chemicals. However, most patients of African descent without this disorder have similar styling habits. Nonetheless, avoidance of physical and chemical trauma to the sc...</description>
            <author>Dermatologic Therapy</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1629563</comments>
            <pubDate>Tue, 15 Jul 2008 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">1629563</guid>        </item>
        <item>
            <title>Central scalp alopecia photographic scale in African&amp;nbsp;American women</title>
            <link>http://www.medworm.com/index.php?rid=1629562&amp;cid=s_31737_12_f&amp;fid=31737&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1529-8019.2008.00208.x</link>
            <description>ABSTRACT: Central centrifugal cicatricial alopecia (CCCA) is a common but poorly understood cause of hair loss in African American women. A photographic scale was developed that captures the pattern and severity of the central hair loss seen with CCCA in order to help identify this problem in the general community and to potentially correlate clinical data with hair loss. The utility and reproducibility of this photographic scale was determined in a group of 150 African American women gathered for a health and beauty day who were evaluated by both four investigators experienced in the diagnosis of hair disorders and by the subjects themselves. (Source: Dermatologic Therapy)</description>
            <author>Dermatologic Therapy</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1629562</comments>
            <pubDate>Tue, 15 Jul 2008 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">1629562</guid>        </item>
        <item>
            <title>Pseudopelade of Brocq</title>
            <link>http://www.medworm.com/index.php?rid=1629561&amp;cid=s_31737_12_f&amp;fid=31737&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1529-8019.2008.00207.x</link>
            <description>ABSTRACT: Pseudopelade of Brocq (PPB) is a rare, idiopathic, slowly progressive hair disorder, resulting in cicatricial alopecia. It typically presents in Caucasian adult patients as small, smooth, flesh-toned and slightly depressed alopecic patches with irregular outlines. It primarily involves the parietal and vertex portions of the scalp with a chronic prolonged course. Controversial opinions still exist as to whether PPB is a single entity or an end stage of several cicatricial alopecic disorders. A practical approach to diagnosis of PPB and therapeutic update are discussed in this review. (Source: Dermatologic Therapy)</description>
            <author>Dermatologic Therapy</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1629561</comments>
            <pubDate>Tue, 15 Jul 2008 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">1629561</guid>        </item>
        <item>
            <title>Lichen planopilaris</title>
            <link>http://www.medworm.com/index.php?rid=1629560&amp;cid=s_31737_12_f&amp;fid=31737&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1529-8019.2008.00206.x</link>
            <description>ABSTRACT: Lichen planopilaris is a chronic scarring alopecia characterized by follicular hyperkeratosis, perifollicular erythema, and loss of follicular orifices. The scalp lesions may be single or multiple and commonly involve the vertex and parietal area. The hair follicles at the margin of the alopecic patches reveal perifollicular erythema. Anagen hairs can be pulled out easily in active lesions. Associated cutaneous, nail, and mucous membrane lichen planus may be present. Commonly encountered symptoms and signs are increased hair shedding, itching, scaling, burning, and tenderness. Differentiation from other cicatricial alopecia can be performed through meticulous evaluation of the clinical, histopathologic, and immunohistopathologic findings. Treatment strategies depend on the diseas...</description>
            <author>Dermatologic Therapy</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1629560</comments>
            <pubDate>Tue, 15 Jul 2008 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">1629560</guid>        </item>
        <item>
            <title>Cicatricial alopecia: discoid lupus erythematosus</title>
            <link>http://www.medworm.com/index.php?rid=1629559&amp;cid=s_31737_12_f&amp;fid=31737&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1529-8019.2008.00205.x</link>
            <description>ABSTRACT: Chronic cutaneous lupus erythematosus consists of three major dermatologic diseases: discoid lupus erythematosus (DLE), lupus panniculitis/lupus profundus, and lupus tumidus (Table 1). DLE is estimated to be responsible for 50[ndash]85% of patients with chronic cutaneous lupus erythematosus. Scalp involvement is most often the presenting symptom. The clinical features and diagnosis of DLE, its pathophysiology and treatment, are reviewed. (Source: Dermatologic Therapy)</description>
            <author>Dermatologic Therapy</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1629559</comments>
            <pubDate>Tue, 15 Jul 2008 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">1629559</guid>        </item>
        <item>
            <title>Folliculitis decalvans</title>
            <link>http://www.medworm.com/index.php?rid=1629558&amp;cid=s_31737_12_f&amp;fid=31737&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1529-8019.2008.00204.x</link>
            <description>ABSTRACT: Folliculitis decalvans is a rare inflammatory scalp disorder. The present paper gives a practical approach to diagnosis and patient management and reviews possible pathogenetic factors and treatment options. Folliculitis decalvans is classified as primary neutrophilic cicatricial alopecia and predominantly occurs in middle-aged adults. Staphylococcus aureus and a deficient host immune response seem to play an important role in the development of this disfiguring scalp disease. Lesions occur mainly in the vertex and occipital area. Clinically, the lesions present with follicular pustules, lack of ostia, diffuse and perifollicular erythema, follicular tufting, and, oftentimes, hemorrhagic crusts and erosions. Histology displays a mainly neutrophilic inflammatory infiltrate in early...</description>
            <author>Dermatologic Therapy</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1629558</comments>
            <pubDate>Tue, 15 Jul 2008 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">1629558</guid>        </item>
        <item>
            <title>Cicatricial alopecia: classification and histopathology</title>
            <link>http://www.medworm.com/index.php?rid=1629557&amp;cid=s_31737_12_f&amp;fid=31737&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1529-8019.2008.00203.x</link>
            <description>ABSTRACT: Primary cicatricial alopecias are a diagnostically challenging group of disorders characterized by folliculocentric inflammation resulting in destruction of hair follicles and irreversible hair loss. They are classified according to a consensus-issued classification scheme based on the predominant cell type present: lymphocytic, neutrophilic, or mixed. Histopathology is a pivotal component of the diagnostic evaluation. Early diagnosis is critical since timely institution of treatment can halt progression of permanent hair loss. Salient histopathologic findings are presented in this review, along with adjunctive clues derived from interpretation of special stains and direct immunofluorescence studies. Despite careful evaluation, accurate diagnosis may remain elusive in some instan...</description>
            <author>Dermatologic Therapy</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1629557</comments>
            <pubDate>Tue, 15 Jul 2008 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">1629557</guid>        </item>
        <item>
            <title>Etiology of cicatricial alopecias: a basic science point of view</title>
            <link>http://www.medworm.com/index.php?rid=1629556&amp;cid=s_31737_12_f&amp;fid=31737&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1529-8019.2008.00202.x</link>
            <description>This article presents a short summary of our current knowledge of cicatricial alopecia disease pathogenesis and the hypothetical disease mechanisms that may be involved in scarring alopecia development. Several forms of scarring alopecia likely involve targeted cytotoxic action against hair follicle cells mediated by a folliculocentric inflammation. However, the specific nature of the inflammatory interference in hair follicle growth is open to question. A popular hypothesis of lymphocyte-mediated scarring alopecia development involves autoimmune targeting of hair follicle[ndash]specific self-antigens, although there is no direct evidence in support of such a view. Alternative hypotheses focus on defects in sebaceous gland function, destruction of hair follicle stem cells, and interference...</description>
            <author>Dermatologic Therapy</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1629556</comments>
            <pubDate>Tue, 15 Jul 2008 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">1629556</guid>        </item>
        <item>
            <title>Cicatricial alopecias</title>
            <link>http://www.medworm.com/index.php?rid=1629555&amp;cid=s_31737_12_f&amp;fid=31737&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1529-8019.2008.00201.x</link>
            <description>(Source: Dermatologic Therapy)</description>
            <author>Dermatologic Therapy</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1629555</comments>
            <pubDate>Tue, 01 Jul 2008 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">1629555</guid>        </item>
        <item>
            <title>Erratum</title>
            <link>http://www.medworm.com/index.php?rid=1612086&amp;cid=s_31737_12_f&amp;fid=31737&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1529-8019.2008.00212.x</link>
            <description>(Source: Dermatologic Therapy)</description>
            <author>Dermatologic Therapy</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1612086</comments>
            <pubDate>Sat, 28 Jun 2008 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">1612086</guid>        </item>
        <item>
            <title>Syphilis and borreliosis during pregnancy</title>
            <link>http://www.medworm.com/index.php?rid=1612085&amp;cid=s_31737_12_f&amp;fid=31737&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1529-8019.2008.00192.x</link>
            <description>ABSTRACT: Syphilis and lyme borreliosis have similar etiologic, clinical, and epidemiologic characteristics. Both are multisystem infectious disorders spread worldwide. Their clinical course can be divided into three stages and as to spirochetal origin, antibiotic therapy is similar too. Taxonomical relationship of Treponema and Borrelia could explain also congenital manifestations well-known in syphilis, and suggested in borreliosis. Therapy of pregnant women with syphilis and lyme borreliosis should follow the same strategy. (Source: Dermatologic Therapy)</description>
            <author>Dermatologic Therapy</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1612085</comments>
            <pubDate>Sat, 28 Jun 2008 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">1612085</guid>        </item>
        <item>
            <title>Recent advances in management of genital ulcer disease and anogenital warts</title>
            <link>http://www.medworm.com/index.php?rid=1612084&amp;cid=s_31737_12_f&amp;fid=31737&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1529-8019.2008.00191.x</link>
            <description>ABSTRACT: Genital ulcer disease (GUD) constitutes a major public health problem. Most of them are the result of sexually transmitted diseases. Genital herpes, syphilis, lymphogranuloma venereum, granuloma venereum, or chancroid are the commonly encountered GUD. The treatment modalities for these disorders have changed with advent and use of drugs such as azithromycin. The treatment modalities differ in patients with HIV disease. Further vaccines for herpes genitalis and human papilloma virus has opened new avenues in management of these diseases. In regions where there are no diagnostic facilities or where the costs of diagnostic tests are prohibitive, syndromic management of GUD is preferred. (Source: Dermatologic Therapy)</description>
            <author>Dermatologic Therapy</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1612084</comments>
            <pubDate>Sat, 28 Jun 2008 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">1612084</guid>        </item>
        <item>
            <title>Local antibiotics in dermatology</title>
            <link>http://www.medworm.com/index.php?rid=1612083&amp;cid=s_31737_12_f&amp;fid=31737&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1529-8019.2008.00190.x</link>
            <description>ABSTRACT: Although the vast majority of skin infection must be treated with systemic antibiotics, topical antibiotics are used overwhelmingly in the world, often as self-prescribed medications without taking into account the sensitivity of the presumed bacteria. Dermatologists are aware that different types of topical antibiotics kill different species of bacteria and tend to be more specific in their prescriptions. At present local antibiotics are advised to treat minor superficial uncomplicated skin infections (e.g., impetigo) and to prevent bacterial infections caused into minor cuts, scrapes, and burns. The role of topical antibiotics in the management of acne and atopic dermatitis is controversial. Retapamulin, a novel topical antibacterial agent, will probably replace the use of the ...</description>
            <author>Dermatologic Therapy</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1612083</comments>
            <pubDate>Sat, 28 Jun 2008 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">1612083</guid>        </item>
        <item>
            <title>How to manage infections in the era of biologics?</title>
            <link>http://www.medworm.com/index.php?rid=1612082&amp;cid=s_31737_12_f&amp;fid=31737&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1529-8019.2008.00189.x</link>
            <description>ABSTRACT: Biologic agents are immunosuppressants that target cytokines or specific immune cell subpopulations. Many therapies interfere with the normal inflammatory cascade and with the immune system, causing an increase in the incidence of infections. In particular, treatment with tumor necrosis factor (TNF)-[alpha] antagonists in psoriasis patients is associated with an increased risk of infection caused by intracellular microorganisms. TNF-[alpha] plays an important role in host resistance against infectious and several cases of Mycobacterium tuberculosis, Listeria monocytogenes, and Pneumocystis carinii have been reported with anti-TNF-[alpha] agents. Furthermore, B and T cells are essential to the immune response; thus, their specific reduction or inhibition by targeting molecules in ...</description>
            <author>Dermatologic Therapy</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1612082</comments>
            <pubDate>Sat, 28 Jun 2008 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">1612082</guid>        </item>
        <item>
            <title>Treatment and prevention of community-associated methicillin-resistant Staphylococcus aureus skin and soft tissue infections</title>
            <link>http://www.medworm.com/index.php?rid=1612081&amp;cid=s_31737_12_f&amp;fid=31737&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1529-8019.2008.00188.x</link>
            <description>ABSTRACT: Community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) has emerged as a pathogen in the community with a range of clinical manifestations. Although skin and soft tissue infections (SSTIs) are the most common presentation, invasive and more virulent disease has been observed. Colonization and infection with CA-MRSA can occur in individuals with no prior healthcare exposures but also in distinct groups whose common characteristic appears to be close person-to-person contact. Outbreaks with CA-MRSA have occurred in day care centers, athletic teams, and prisons, and transmission has been documented among family members and within the hospital. Treatment of SSTIs involves incision and drainage, oral or parenteral antibiotic therapy, or topical therapy. Healthcare p...</description>
            <author>Dermatologic Therapy</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1612081</comments>
            <pubDate>Sat, 28 Jun 2008 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">1612081</guid>        </item>
        <item>
            <title>Therapy of environmental mycobacterial infections</title>
            <link>http://www.medworm.com/index.php?rid=1612080&amp;cid=s_31737_12_f&amp;fid=31737&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1529-8019.2008.00187.x</link>
            <description>ABSTRACT: Environmental mycobacteria are the causative factors of an increasing number of infections worldwide. Cutaneous infections as a result of environmental mycobacteria are often misdiagnosed, and their treatment is difficult because these agents can show in vivo and in vitro multidrug resistance. The most common environmental mycobacteria that can cause cutaneous infections are Mycobacterium fortuitum and Mycobacterium marinum. All mycobacteria are characterized by low pathogenicity and they can contaminate affected or traumatized skin only in immunocompetent subjects (mainly in fishermen, swimming-pool attendants, and aquarium owners) whereas medical and esthetic procedures are at risk for the infections because of the quick-growing mycobacteria. Immunocompromised subjects can inst...</description>
            <author>Dermatologic Therapy</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1612080</comments>
            <pubDate>Sat, 28 Jun 2008 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">1612080</guid>        </item>
        <item>
            <title>Management of cutaneous tuberculosis</title>
            <link>http://www.medworm.com/index.php?rid=1612079&amp;cid=s_31737_12_f&amp;fid=31737&amp;url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1529-8019.2008.00186.x</link>
            <description>ABSTRACT: Cutaneous tuberculosis (TB) is an extrapulmonary form of tuberculosis, which may be classified based on the immunologic state of the host. Chemotherapy still remains the treatment of choice. The management of cutaneous TB follows the same guidelines as that of TB of other organs, which can be treated with a short course four-agent chemotherapeutic regimen given for 2 months followed by a two-drug regimen for the next 4 months. This chapter highlights current treatment recommendations for cutaneous TB. The important factors to consider in the choice of optimal treatment includes the type of cutaneous involvement, stage of the disease, level of immunity, and general condition of the patient. The highest priority in any cutaneous TB control program is the proper, accurate, and rapid...</description>
            <author>Dermatologic Therapy</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1612079</comments>
            <pubDate>Sat, 28 Jun 2008 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">1612079</guid>        </item>
        <item>
            <title>Treatment of cutaneous infections</title>
            <link>http://www.medworm.com/index.php?rid=1510646&amp;cid=s_31737_12_f&amp;fid=31737&amp;url=http%3A%2F%2Fwww.blackwell-synergy.com%2Fdoi%2Fabs%2F10.1111%2Fj.1529-8019.2008.00185.x%3Fai%3Dyo%26mi%3D4mpuw%26af%3DR</link>
            <description>Dermatologic Therapy, Volume 21, Issue 3, Page 153, May/June 2008. (Source: Dermatologic Therapy)</description>
            <author>Dermatologic Therapy</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1510646</comments>
            <pubDate>Thu, 12 Jun 2008 18:15:37 +0100</pubDate>
            <guid isPermaLink="false">1510646</guid>        </item>
        <item>
            <title>Local antibiotics in dermatology</title>
            <link>http://www.medworm.com/index.php?rid=1510651&amp;cid=s_31737_12_f&amp;fid=31737&amp;url=http%3A%2F%2Fwww.blackwell-synergy.com%2Fdoi%2Fabs%2F10.1111%2Fj.1529-8019.2008.00190.x%3Fai%3Dyo%26mi%3D4mpuw%26af%3DR</link>
            <description>Dermatologic Therapy, Volume 21, Issue 3, Page 187-195, May/June 2008. 
		
	 ABSTRACT:  Although the vast majority of skin infection must be treated with systemic antibiotics, topical antibiotics are used overwhelmingly in the world, often as self-prescribed medications without taking into account the sensitivity of the presumed ... (Source: Dermatologic Therapy)</description>
            <author>Dermatologic Therapy</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1510651</comments>
            <pubDate>Thu, 12 Jun 2008 16:07:30 +0100</pubDate>
            <guid isPermaLink="false">1510651</guid>        </item>
        <item>
            <title>Syphilis and borreliosis during pregnancy</title>
            <link>http://www.medworm.com/index.php?rid=1510653&amp;cid=s_31737_12_f&amp;fid=31737&amp;url=http%3A%2F%2Fwww.blackwell-synergy.com%2Fdoi%2Fabs%2F10.1111%2Fj.1529-8019.2008.00192.x%3Fai%3Dyo%26mi%3D4mpuw%26af%3DR</link>
            <description>Dermatologic Therapy, Volume 21, Issue 3, Page 205-209, May/June 2008. 
		
	 ABSTRACT:  Syphilis and lyme borreliosis have similar etiologic, clinical, and epidemiologic characteristics. Both are multisystem infectious disorders spread worldwide. Their clinical course can be divided into three stages and as to spirochetal origin, ... (Source: Dermatologic Therapy)</description>
            <author>Dermatologic Therapy</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1510653</comments>
            <pubDate>Thu, 12 Jun 2008 16:07:28 +0100</pubDate>
            <guid isPermaLink="false">1510653</guid>        </item>
        <item>
            <title>Management of cutaneous tuberculosis</title>
            <link>http://www.medworm.com/index.php?rid=1510647&amp;cid=s_31737_12_f&amp;fid=31737&amp;url=http%3A%2F%2Fwww.blackwell-synergy.com%2Fdoi%2Fabs%2F10.1111%2Fj.1529-8019.2008.00186.x%3Fai%3Dyo%26mi%3D4mpuw%26af%3DR</link>
            <description>Dermatologic Therapy, Volume 21, Issue 3, Page 154-161, May/June 2008. 
		
	 ABSTRACT:  Cutaneous tuberculosis (TB) is an extrapulmonary form of tuberculosis, which may be classified based on the immunologic state of the host. Chemotherapy still remains the treatment of choice. The management of cutaneous TB follows the same ... (Source: Dermatologic Therapy)</description>
            <author>Dermatologic Therapy</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1510647</comments>
            <pubDate>Thu, 12 Jun 2008 16:07:27 +0100</pubDate>
            <guid isPermaLink="false">1510647</guid>        </item>
        <item>
            <title>Therapy of environmental mycobacterial infections</title>
            <link>http://www.medworm.com/index.php?rid=1510648&amp;cid=s_31737_12_f&amp;fid=31737&amp;url=http%3A%2F%2Fwww.blackwell-synergy.com%2Fdoi%2Fabs%2F10.1111%2Fj.1529-8019.2008.00187.x%3Fai%3Dyo%26mi%3D4mpuw%26af%3DR</link>
            <description>Dermatologic Therapy, Volume 21, Issue 3, Page 162-166, May/June 2008. 
		
	 ABSTRACT:  Environmental mycobacteria are the causative factors of an increasing number of infections worldwide. Cutaneous infections as a result of environmental mycobacteria are often misdiagnosed, and their treatment is difficult because these agents ... (Source: Dermatologic Therapy)</description>
            <author>Dermatologic Therapy</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1510648</comments>
            <pubDate>Thu, 12 Jun 2008 16:07:22 +0100</pubDate>
            <guid isPermaLink="false">1510648</guid>        </item>
        <item>
            <title>Treatment and prevention of community-associated methicillin-resistant Staphylococcus aureus skin and soft tissue infections</title>
            <link>http://www.medworm.com/index.php?rid=1510649&amp;cid=s_31737_12_f&amp;fid=31737&amp;url=http%3A%2F%2Fwww.blackwell-synergy.com%2Fdoi%2Fabs%2F10.1111%2Fj.1529-8019.2008.00188.x%3Fai%3Dyo%26mi%3D4mpuw%26af%3DR</link>
            <description>Dermatologic Therapy, Volume 21, Issue 3, Page 167-179, May/June 2008. 
		
	 ABSTRACT:  Community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) has emerged as a pathogen in the community with a range of clinical manifestations. Although skin and soft tissue infections (SSTIs) are the most common presentation, ... (Source: Dermatologic Therapy)</description>
            <author>Dermatologic Therapy</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1510649</comments>
            <pubDate>Thu, 12 Jun 2008 16:07:20 +0100</pubDate>
            <guid isPermaLink="false">1510649</guid>        </item>
        <item>
            <title>Erratum: Erratum</title>
            <link>http://www.medworm.com/index.php?rid=1510654&amp;cid=s_31737_12_f&amp;fid=31737&amp;url=http%3A%2F%2Fwww.blackwell-synergy.com%2Fdoi%2Fabs%2F10.1111%2Fj.1529-8019.2008.00212.x%3Fai%3Dyo%26mi%3D4mpuw%26af%3DR</link>
            <description>Dermatologic Therapy, Volume 21, Issue 3, Page 210, May/June 2008. (Source: Dermatologic Therapy)</description>
            <author>Dermatologic Therapy</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1510654</comments>
            <pubDate>Thu, 12 Jun 2008 16:07:19 +0100</pubDate>
            <guid isPermaLink="false">1510654</guid>        </item>
        <item>
            <title>Recent advances in management of genital ulcer disease and anogenital warts</title>
            <link>http://www.medworm.com/index.php?rid=1510652&amp;cid=s_31737_12_f&amp;fid=31737&amp;url=http%3A%2F%2Fwww.blackwell-synergy.com%2Fdoi%2Fabs%2F10.1111%2Fj.1529-8019.2008.00191.x%3Fai%3Dyo%26mi%3D4mpuw%26af%3DR</link>
            <description>Dermatologic Therapy, Volume 21, Issue 3, Page 196-204, May/June 2008. 
		
	 ABSTRACT:  Genital ulcer disease (GUD) constitutes a major public health problem. Most of them are the result of sexually transmitted diseases. Genital herpes, syphilis, lymphogranuloma venereum, granuloma venereum, or chancroid are the commonly ... (Source: Dermatologic Therapy)</description>
            <author>Dermatologic Therapy</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1510652</comments>
            <pubDate>Thu, 12 Jun 2008 16:07:15 +0100</pubDate>
            <guid isPermaLink="false">1510652</guid>        </item>
        <item>
            <title>How to manage infections in the era of biologics?</title>
            <link>http://www.medworm.com/index.php?rid=1510650&amp;cid=s_31737_12_f&amp;fid=31737&amp;url=http%3A%2F%2Fwww.blackwell-synergy.com%2Fdoi%2Fabs%2F10.1111%2Fj.1529-8019.2008.00189.x%3Fai%3Dyo%26mi%3D4mpuw%26af%3DR</link>
            <description>Dermatologic Therapy, Volume 21, Issue 3, Page 180-186, May/June 2008. 
		
	 ABSTRACT:  Biologic agents are immunosuppressants that target cytokines or specific immune cell subpopulations. Many therapies interfere with the normal inflammatory cascade and with the immune system, causing an increase in the incidence of infections. ... (Source: Dermatologic Therapy)</description>
            <author>Dermatologic Therapy</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1510650</comments>
            <pubDate>Thu, 12 Jun 2008 16:07:15 +0100</pubDate>
            <guid isPermaLink="false">1510650</guid>        </item>
        <item>
            <title>Dermatologic Therapy issue on &quot;New and Emerging Treatments in Dermatology&quot;</title>
            <link>http://www.medworm.com/index.php?rid=1350497&amp;cid=s_31737_12_f&amp;fid=31737&amp;url=http%3A%2F%2Fwww.blackwell-synergy.com%2Fdoi%2Fabs%2F10.1111%2Fj.1529-8019.2008.00174.x%3Fai%3Dyo%26mi%3D4mpuw%26af%3DR</link>
            <description>Dermatologic Therapy, Volume 21, Issue 2, Page 85, March/April 2008. (Source: Dermatologic Therapy)</description>
            <author>Dermatologic Therapy</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1350497</comments>
            <pubDate>Fri, 04 Apr 2008 18:15:24 +0100</pubDate>
            <guid isPermaLink="false">1350497</guid>        </item>
        <item>
            <title>Esthetic and cosmetic dermatology</title>
            <link>http://www.medworm.com/index.php?rid=1350502&amp;cid=s_31737_12_f&amp;fid=31737&amp;url=http%3A%2F%2Fwww.blackwell-synergy.com%2Fdoi%2Fabs%2F10.1111%2Fj.1529-8019.2008.00179.x%3Fai%3Dyo%26mi%3D4mpuw%26af%3DR</link>
            <description>Dermatologic Therapy, Volume 21, Issue 2, Page 118-130, March/April 2008. 
		
	 ABSTRACT: The field of esthetic and cosmetic dermatology has gained remarkable interest all over the world. The major advantage of recent years is the high scientific levels of the most significant new developments in techniques and pharmacotherapy and ... (Source: Dermatologic Therapy)</description>
            <author>Dermatologic Therapy</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1350502</comments>
            <pubDate>Thu, 03 Apr 2008 19:02:24 +0100</pubDate>
            <guid isPermaLink="false">1350502</guid>        </item>
        <item>
            <title>Erratum: Erratum</title>
            <link>http://www.medworm.com/index.php?rid=1350505&amp;cid=s_31737_12_f&amp;fid=31737&amp;url=http%3A%2F%2Fwww.blackwell-synergy.com%2Fdoi%2Fabs%2F10.1111%2Fj.1529-8019.2008.00183.x%3Fai%3Dyo%26mi%3D4mpuw%26af%3DR</link>
            <description>Dermatologic Therapy, Volume 21, Issue 2, Page 150, March/April 2008. (Source: Dermatologic Therapy)</description>
            <author>Dermatologic Therapy</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1350505</comments>
            <pubDate>Thu, 03 Apr 2008 19:02:23 +0100</pubDate>
            <guid isPermaLink="false">1350505</guid>        </item>
        <item>
            <title>Atopic dermatitis</title>
            <link>http://www.medworm.com/index.php?rid=1350499&amp;cid=s_31737_12_f&amp;fid=31737&amp;url=http%3A%2F%2Fwww.blackwell-synergy.com%2Fdoi%2Fabs%2F10.1111%2Fj.1529-8019.2008.00176.x%3Fai%3Dyo%26mi%3D4mpuw%26af%3DR</link>
            <description>Dermatologic Therapy, Volume 21, Issue 2, Page 96-100, March/April 2008. 
		
	 ABSTRACT: Atopic dermatitis (AD) is a common dermatologic disease that can occur at different ages with different clinical manifestations. The etiologic factors and the pathogenetic pathways of AD have been thoroughly investigated but as often happens, ... (Source: Dermatologic Therapy)</description>
            <author>Dermatologic Therapy</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1350499</comments>
            <pubDate>Thu, 03 Apr 2008 19:02:22 +0100</pubDate>
            <guid isPermaLink="false">1350499</guid>        </item>
        <item>
            <title>New and emerging treatments in dermatology: acne</title>
            <link>http://www.medworm.com/index.php?rid=1350498&amp;cid=s_31737_12_f&amp;fid=31737&amp;url=http%3A%2F%2Fwww.blackwell-synergy.com%2Fdoi%2Fabs%2F10.1111%2Fj.1529-8019.2008.00175.x%3Fai%3Dyo%26mi%3D4mpuw%26af%3DR</link>
            <description>Dermatologic Therapy, Volume 21, Issue 2, Page 86-95, March/April 2008. 
		
	 ABSTRACT: Topical retinoids, benzoyl peroxide, azelaic acid, and topical and oral antibiotics remain the milestone of treatment for mild to moderate acne vulgaris. Oral isotretinoin is useful for the treatment of severe nodular acne, treatment-resistant ... (Source: Dermatologic Therapy)</description>
            <author>Dermatologic Therapy</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1350498</comments>
            <pubDate>Thu, 03 Apr 2008 19:02:04 +0100</pubDate>
            <guid isPermaLink="false">1350498</guid>        </item>
        <item>
            <title>From conventional to cutting edge: the new era of biologics in treatment of psoriasis</title>
            <link>http://www.medworm.com/index.php?rid=1350503&amp;cid=s_31737_12_f&amp;fid=31737&amp;url=http%3A%2F%2Fwww.blackwell-synergy.com%2Fdoi%2Fabs%2F10.1111%2Fj.1529-8019.2008.00180.x%3Fai%3Dyo%26mi%3D4mpuw%26af%3DR</link>
            <description>Dermatologic Therapy, Volume 21, Issue 2, Page 131-141, March/April 2008. 
		
	 ABSTRACT: Psoriasis is a chronic T-cell-mediated inflammatory disease of the skin and joints that affects 1–3% of the world population. Conventional treatments for moderate to severe psoriasis are associated with broadband immunosuppression and/or organ ... (Source: Dermatologic Therapy)</description>
            <author>Dermatologic Therapy</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1350503</comments>
            <pubDate>Thu, 03 Apr 2008 19:02:01 +0100</pubDate>
            <guid isPermaLink="false">1350503</guid>        </item>
        <item>
            <title>Erratum: Erratum</title>
            <link>http://www.medworm.com/index.php?rid=1350506&amp;cid=s_31737_12_f&amp;fid=31737&amp;url=http%3A%2F%2Fwww.blackwell-synergy.com%2Fdoi%2Fabs%2F10.1111%2Fj.1529-8019.2008.00184.x%3Fai%3Dyo%26mi%3D4mpuw%26af%3DR</link>
            <description>Dermatologic Therapy, Volume 21, Issue 2, Page 151, March/April 2008. (Source: Dermatologic Therapy)</description>
            <author>Dermatologic Therapy</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1350506</comments>
            <pubDate>Thu, 03 Apr 2008 19:01:50 +0100</pubDate>
            <guid isPermaLink="false">1350506</guid>        </item>
        <item>
            <title>What's new in dermatologic therapy</title>
            <link>http://www.medworm.com/index.php?rid=1350504&amp;cid=s_31737_12_f&amp;fid=31737&amp;url=http%3A%2F%2Fwww.blackwell-synergy.com%2Fdoi%2Fabs%2F10.1111%2Fj.1529-8019.2008.00181.x%3Fai%3Dyo%26mi%3D4mpuw%26af%3DR</link>
            <description>This article reviews important recent advances in dermatologic therapy and their impact on patient management. (Source: Dermatologic Therapy)</description>
            <author>Dermatologic Therapy</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1350504</comments>
            <pubDate>Thu, 03 Apr 2008 19:01:50 +0100</pubDate>
            <guid isPermaLink="false">1350504</guid>        </item>
        <item>
            <title>Lyme borreliosis treatment</title>
            <link>http://www.medworm.com/index.php?rid=1350500&amp;cid=s_31737_12_f&amp;fid=31737&amp;url=http%3A%2F%2Fwww.blackwell-synergy.com%2Fdoi%2Fabs%2F10.1111%2Fj.1529-8019.2008.00177.x%3Fai%3Dyo%26mi%3D4mpuw%26af%3DR</link>
            <description>Dermatologic Therapy, Volume 21, Issue 2, Page 101-109, March/April 2008. 
		
	 ABSTRACT: Lyme borreliosis is the most common human tick-borne illness in the Northern Hemisphere. The causative agent is the spirochete Borrelia burgdorferi species complex, and the hard-shell ticks of the genus Ixodes is responsible for pathogen ... (Source: Dermatologic Therapy)</description>
            <author>Dermatologic Therapy</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1350500</comments>
            <pubDate>Thu, 03 Apr 2008 19:01:46 +0100</pubDate>
            <guid isPermaLink="false">1350500</guid>        </item>
        <item>
            <title>Vitiligo: new and emerging treatments</title>
            <link>http://www.medworm.com/index.php?rid=1350501&amp;cid=s_31737_12_f&amp;fid=31737&amp;url=http%3A%2F%2Fwww.blackwell-synergy.com%2Fdoi%2Fabs%2F10.1111%2Fj.1529-8019.2008.00178.x%3Fai%3Dyo%26mi%3D4mpuw%26af%3DR</link>
            <description>Dermatologic Therapy, Volume 21, Issue 2, Page 110-117, March/April 2008. 
		
	 ABSTRACT: Vitiligo is a cosmetically disfiguring condition, and, although there is no therapeutic full solution yet, some treatment may induce good results in most patients. The disease can be successfully treated with various medical options. Both ... (Source: Dermatologic Therapy)</description>
            <author>Dermatologic Therapy</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1350501</comments>
            <pubDate>Thu, 03 Apr 2008 19:01:27 +0100</pubDate>
            <guid isPermaLink="false">1350501</guid>        </item>
        <item>
            <title>Treatment of psychocutaneous diseases</title>
            <link>http://www.medworm.com/index.php?rid=1279820&amp;cid=s_31737_12_f&amp;fid=31737&amp;url=http%3A%2F%2Fwww.blackwell-synergy.com%2Fdoi%2Fabs%2F10.1111%2Fj.1529-8019.2008.00162.x%3Fai%3Dyo%26mi%3D4mpuw%26af%3DR</link>
            <description>Dermatologic Therapy, Volume 21, Issue 1, Page 1, January 2008. (Source: Dermatologic Therapy)</description>
            <author>Dermatologic Therapy</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1279820</comments>
            <pubDate>Wed, 05 Mar 2008 19:13:13 +0100</pubDate>
            <guid isPermaLink="false">1279820</guid>        </item>
        <item>
            <title>The psychosocial and occupational impact of chronic skin disease</title>
            <link>http://www.medworm.com/index.php?rid=1279828&amp;cid=s_31737_12_f&amp;fid=31737&amp;url=http%3A%2F%2Fwww.blackwell-synergy.com%2Fdoi%2Fabs%2F10.1111%2Fj.1529-8019.2008.00170.x%3Fai%3Dyo%26mi%3D4mpuw%26af%3DR</link>
            <description>Dermatologic Therapy, Volume 21, Issue 1, Page 54-59, January 2008. 
		
	 ABSTRACT: Chronic skin diseases, particularly psoriasis and atopic dermatitis, have a negative impact on patients’ quality of life. Patients often experience significant psychological and social distress such as increased levels of depression and fear ... (Source: Dermatologic Therapy)</description>
            <author>Dermatologic Therapy</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1279828</comments>
            <pubDate>Tue, 04 Mar 2008 21:47:26 +0100</pubDate>
            <guid isPermaLink="false">1279828</guid>        </item>
        <item>
            <title>Delusions of parasitosis</title>
            <link>http://www.medworm.com/index.php?rid=1279821&amp;cid=s_31737_12_f&amp;fid=31737&amp;url=http%3A%2F%2Fwww.blackwell-synergy.com%2Fdoi%2Fabs%2F10.1111%2Fj.1529-8019.2008.00163.x%3Fai%3Dyo%26mi%3D4mpuw%26af%3DR</link>
            <description>Dermatologic Therapy, Volume 21, Issue 1, Page 2-7, January 2008. 
		
	 ABSTRACT: Delusions of parasitosis is a rare psychiatric disorder in which the patient has a fixed, false belief that he or she is infested by parasites. Even though it is a psychiatric disorder, these patients usually present to a dermatologist because ... (Source: Dermatologic Therapy)</description>
            <author>Dermatologic Therapy</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1279821</comments>
            <pubDate>Tue, 04 Mar 2008 21:47:24 +0100</pubDate>
            <guid isPermaLink="false">1279821</guid>        </item>
        <item>
            <title>Prurigo nodularis and lichen simplex chronicus</title>
            <link>http://www.medworm.com/index.php?rid=1279826&amp;cid=s_31737_12_f&amp;fid=31737&amp;url=http%3A%2F%2Fwww.blackwell-synergy.com%2Fdoi%2Fabs%2F10.1111%2Fj.1529-8019.2008.00168.x%3Fai%3Dyo%26mi%3D4mpuw%26af%3DR</link>
            <description>Dermatologic Therapy, Volume 21, Issue 1, Page 42-46, January 2008. 
		
	 ABSTRACT: Emotional tensions in predisposed subjects may play a key role in inducing a pruritic sensation, leading to a scratching that, becoming a self-perpetuating pathomechanism, may represent the main feature of two distinct cutaneous clinical ... (Source: Dermatologic Therapy)</description>
            <author>Dermatologic Therapy</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1279826</comments>
            <pubDate>Tue, 04 Mar 2008 21:47:20 +0100</pubDate>
            <guid isPermaLink="false">1279826</guid>        </item>
        <item>
            <title>Erratum: Erratum</title>
            <link>http://www.medworm.com/index.php?rid=1279831&amp;cid=s_31737_12_f&amp;fid=31737&amp;url=http%3A%2F%2Fwww.blackwell-synergy.com%2Fdoi%2Fabs%2F10.1111%2Fj.1529-8019.2008.00182.x%3Fai%3Dyo%26mi%3D4mpuw%26af%3DR</link>
            <description>Dermatologic Therapy, Volume 21, Issue 1, Page 83, January 2008. (Source: Dermatologic Therapy)</description>
            <author>Dermatologic Therapy</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1279831</comments>
            <pubDate>Tue, 04 Mar 2008 21:47:19 +0100</pubDate>
            <guid isPermaLink="false">1279831</guid>        </item>
        <item>
            <title>Nonpharmacologic management of common skin and psychocutaneous disorders</title>
            <link>http://www.medworm.com/index.php?rid=1279829&amp;cid=s_31737_12_f&amp;fid=31737&amp;url=http%3A%2F%2Fwww.blackwell-synergy.com%2Fdoi%2Fabs%2F10.1111%2Fj.1529-8019.2008.00171.x%3Fai%3Dyo%26mi%3D4mpuw%26af%3DR</link>
            <description>Dermatologic Therapy, Volume 21, Issue 1, Page 60-68, January 2008. 
		
	 ABSTRACT: Data supporting the effectiveness of nonpharmacologic psychocutaneous techniques continues to accumulate. These interventions are used for the treatment of common and psychocutaneous skin conditions. They are most commonly used as adjuncts to ... (Source: Dermatologic Therapy)</description>
            <author>Dermatologic Therapy</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1279829</comments>
            <pubDate>Tue, 04 Mar 2008 21:47:11 +0100</pubDate>
            <guid isPermaLink="false">1279829</guid>        </item>
        <item>
            <title>Psychopharmacology in dermatology</title>
            <link>http://www.medworm.com/index.php?rid=1279830&amp;cid=s_31737_12_f&amp;fid=31737&amp;url=http%3A%2F%2Fwww.blackwell-synergy.com%2Fdoi%2Fabs%2F10.1111%2Fj.1529-8019.2008.00172.x%3Fai%3Dyo%26mi%3D4mpuw%26af%3DR</link>
            <description>Dermatologic Therapy, Volume 21, Issue 1, Page 69-82, January 2008. 
		
	 ABSTRACT: Many patients with skin disorders have psychologic issues associated with their chief complaints. Dermatologists who wish to help their patients with psychodermatologic conditions can greatly enhance their therapeutic armamentarium by becoming ... (Source: Dermatologic Therapy)</description>
            <author>Dermatologic Therapy</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1279830</comments>
            <pubDate>Tue, 04 Mar 2008 21:47:09 +0100</pubDate>
            <guid isPermaLink="false">1279830</guid>        </item>
        <item>
            <title>Understanding the psychology of the cosmetic patients</title>
            <link>http://www.medworm.com/index.php?rid=1279827&amp;cid=s_31737_12_f&amp;fid=31737&amp;url=http%3A%2F%2Fwww.blackwell-synergy.com%2Fdoi%2Fabs%2F10.1111%2Fj.1529-8019.2008.00169.x%3Fai%3Dyo%26mi%3D4mpuw%26af%3DR</link>
            <description>Dermatologic Therapy, Volume 21, Issue 1, Page 47-53, January 2008. 
		
	 ABSTRACT: Patients seeking cosmetic surgery commonly present with psychiatric disorders including body dysmorphic disorder, narcissistic personality disorder, and histrionic personality disorder. A basic understanding of the characteristic features of ... (Source: Dermatologic Therapy)</description>
            <author>Dermatologic Therapy</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1279827</comments>
            <pubDate>Tue, 04 Mar 2008 21:47:01 +0100</pubDate>
            <guid isPermaLink="false">1279827</guid>        </item>
        <item>
            <title>Neuropathic and psychogenic itch</title>
            <link>http://www.medworm.com/index.php?rid=1279825&amp;cid=s_31737_12_f&amp;fid=31737&amp;url=http%3A%2F%2Fwww.blackwell-synergy.com%2Fdoi%2Fabs%2F10.1111%2Fj.1529-8019.2008.00167.x%3Fai%3Dyo%26mi%3D4mpuw%26af%3DR</link>
            <description>Dermatologic Therapy, Volume 21, Issue 1, Page 32-41, January 2008. 
		
	 ABSTRACT: Neuropathic and psychogenic itch are two entities that have not been well studied. Neuropathic itch is related to pathology located at any point along the afferent pathway of the nervous system. It could be related to damage to the peripheral ... (Source: Dermatologic Therapy)</description>
            <author>Dermatologic Therapy</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1279825</comments>
            <pubDate>Tue, 04 Mar 2008 21:46:56 +0100</pubDate>
            <guid isPermaLink="false">1279825</guid>        </item>
        <item>
            <title>Morgellons disease?</title>
            <link>http://www.medworm.com/index.php?rid=1279822&amp;cid=s_31737_12_f&amp;fid=31737&amp;url=http%3A%2F%2Fwww.blackwell-synergy.com%2Fdoi%2Fabs%2F10.1111%2Fj.1529-8019.2008.00164.x%3Fai%3Dyo%26mi%3D4mpuw%26af%3DR</link>
            <description>Dermatologic Therapy, Volume 21, Issue 1, Page 8-12, January 2008. 
		
	 ABSTRACT: Morgellons disease, a pattern of dermatologic symptoms very similar, if not identical, to those of delusions of parasitosis, was first described many centuries ago, but has recently been given much attention on the internet and in the mass ... (Source: Dermatologic Therapy)</description>
            <author>Dermatologic Therapy</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1279822</comments>
            <pubDate>Tue, 04 Mar 2008 21:46:56 +0100</pubDate>
            <guid isPermaLink="false">1279822</guid>        </item>
    </channel>
</rss>
